Introduction {#s1}
============

Lipid metabolism is a major component of the eukaryotic strategy for organizing and regulating cell signaling. This involvement is exemplified by the metabolism of phosphatidylinositol (PtdIns) and its phosphorylated derivatives -- the phosphoinositides. Even though eukaryotes only produce five to seven chemically distinct phosphoinositide classes ([@bib6]; [@bib18]; [@bib66]; [@bib20]), these lipids contribute to the control of a broad set of cellular processes. How such diversity of biological outcome is achieved from such a limited set of chemical codes is not well understood. New insights into the mechanisms by which biological outcomes of phosphoinositide signaling are diversified come from studies of how PtdIns-4-phosphate (PtdIns4P) signaling is channeled to specific biological outcomes. In that case, the PtdIns 4-OH kinases are biologically insufficient enzymes that are unable to generate sufficient PtdIns4P to override the action of erasers of PtdIns4P signaling, such as lipid phosphatases and PtdIns4P-sequestering activities, to support productive signaling. These deficiencies are overcome by the action of Sec14-like PtdIns transfer proteins (PITPs) that stimulate PtdIns 4-OH kinase activities so that sufficient PtdIns4P pools are generated in a precisely regulated manner ([@bib32]). It is through this general strategy that individual Sec14-like PITPs channel PtdIns 4-OH kinase activities to specific biological outcomes ([@bib58]; [@bib8]; [@bib48]; [@bib27]).

The biological importance of PITPs in regulating phosphoinositide metabolism is demonstrated by the expansion of the Sec14-like PITPs into the large Sec14 protein superfamily united by a conserved Sec14-fold ([@bib59]; [@bib57]; [@bib58]; [@bib30]), and by the striking phenotypes associated with loss-of-function of individual PITPs in biological systems that range from yeast ([@bib7]; [@bib70]; [@bib55]; [@bib31]), to plants ([@bib51]; [@bib65]; [@bib26]; [@bib30]), and to vertebrates ([@bib29]; [@bib5]; [@bib36]). Sec14-like PITPs potentiate activities of PtdIns 4-OH kinases via a heterotypic lipid exchange cycle between a membrane-docked PITP molecules and the bilayer where the dynamics of an abortive exchange of a 'priming' lipid for PtdIns exposes the PtdIns to the lipid kinase catalytic site. In this way, the lipid exchange cycle renders PtdIns a superior substrate for the enzyme. Structure-based predictions that PtdIns-binding is conserved across the Sec14 superfamily, while the nature of the priming lipid is diversified, suggests a mechanism where the PITP acts as a metabolic sensor for activating PtdIns4P signaling in response to a metabolic input ([@bib58]; [@bib8]; [@bib27]).

As all characterized Sec14-like PITPs are lipid-binding proteins, interrogation of the priming ligand question has focused on lipids as it is widely presumed that lipid exchange/transfer activity is the common feature amongst these proteins. Recent work suggests the ligand menu for Sec14-like proteins might be broader than previously thought, however. Of the six Sec14-like PITPs expressed in yeast, Sfh5 exhibits several distinguishing properties. First, it is the most divergent member of the group as Sfh5 shares the lowest amino acid sequence homology (17.4% identity/33% similarity) with Sec14. Second, Sfh5 is the only yeast Sec14-like protein that exhibits low levels of PtdIns-transfer activity in vitro, and even high levels of Sfh5 expression fail to rescue the growth phenotypes associated with reduced activity of Sec14 in vivo ([@bib41]). Third, the electrostatic properties of Sfh5 are unique among the cohort of yeast Sec14-like PITPs as both the protein surface and large regions of the putative lipid-binding cavity exhibit significant electropositive character -- suggesting Sfh5 does not bind a lipid ([@bib63]).

Herein, we describe a biophysical and structural characterization of Sfh5. We report Sfh5 is a novel penta-coordinate high spin Fe^3+^ heme-binding protein conserved across the fungal kingdom that exhibits unusual heme-binding properties. While the biological functions of Sfh5 remain to be determined, chemogenomic analyses forecast Sfh5 plays a role in organic oxidant-induced stress responses. As such, Sfh5 is the founding member of a new and conserved class of fungal hemoproteins, and provides the first demonstration that the spectrum of ligands for PITP-like proteins extends beyond lipids.

Results {#s2}
=======

The unconventional Sec14-like PITP Sfh5 is a heme-binding protein {#s2-1}
-----------------------------------------------------------------

The unusual biochemical properties ascribed to Sfh5 became particularly evident when the recombinant protein was overexpressed in bacteria. Within a few hours after induction, the producing bacteria acquired a distinct reddish color. Moreover, the purified recombinant His~6~-Sfh5 itself exhibited an intense reddish-brown color which was resistant to dialysis or gel filtration -- suggesting a tightly-bound transition metal ([Figure 1A](#fig1){ref-type="fig"}). Inductively coupled plasma mass spectrometry (ICP-MS) analysis of purified His~6~-Sfh5 identified the bound metal as Fe, and quantification indicated an Fe/Sfh5 molar ratio of 0.33. Moreover, Sfh5 exhibited a Soret peak with an absorption maximum at 404 nm -- the spectral signature of an Fe^3+^ heme ([Figure 1B](#fig1){ref-type="fig"}). In support of this interpretation, sodium dithionite treatment of purified Sfh5 induced a red-shift of the Soret peak to 427 nm -- signifying reduction to the Fe^2+^ state. Reduction of purified recombinant Sfh5 in the context of pyridine hemochromagen assays revealed the formation of additional spectral peaks at 525 nm and 557 nm ([Figure 1B](#fig1){ref-type="fig"}, inset). Those peaks were diagnostic of β- and α-bands, respectively, of non-covalently bound heme *b* ([@bib25]; [@bib10]; [@bib9]). From the spectral intensity measurements in those assays,\~30% of the purified Sfh5 was estimated to be loaded with heme *b* \-- a value consistent with the stoichiometry derived from ICP-MS analyses.

![Sfh5 is a heme-binding protein.\
(**A**) Cell pellets of *E. coli* BL21(DE3) culture expressing Sfh5 are reddish brown color (left panel) relative to cell pellets of BL21(DE3) expressing Sec14 (middle panel). Panel at right shows an image of a purified recombinant Sfh5 (500 µM) solution which is distinguished by a deep reddish brown color. (**B**) UV-vis absorption spectrum of purified Sfh5 is traced in black. Spectra in red identify the spectral profile of Sfh5 after reduction with dithionite. Inset shows the 500 to 650 nm region of the UV-vis spectrum from pyridine hemochromagen assays. The indicated β and α bands at 525 and 557 nm, respectively, diagnose a noncovalently-bound heme *b*. (**C**) Top left: UV-vis absorption spectrum of a clarified cell lysate prepared from *E. coli* expressing Sfh5 absent an N' terminal 8xHis tag. The spectra were calibrated against a cell lysate prepared in parallel from mock-expressing *E. coli* cells (vector-only). Top left: The UV-vis absorption spectrum of clarified cell lysate prepared from *E. coli* BL21 (DE3) cells expressing tag-less Sfh5. Mock lysate prepared from *E. coli* BL21 (DE3) cells was used as blank to calibrate the spectrophotometer. Both *E. coli* cultures were induced with 100 µM IPTG and incubated overnight at 16 °C prior to harvesting and lysing cells. Top right: MALDI-TOF mass spectrum signature of hemin (positive standard), Bottom left and bottom right panels show the heme signatures of purified recombinant Sfh5 and Sfh5 purified directly from *S. cerevisiae*, respectively. Peaks at 616 ± 2 Da constitute a signature for protoporphyrin IX. Total spectral counts within the indicated m/z ranges were as follows: hemin, 30821; recombinant Sfh5, 8038; *S. cerevisiae* Sfh5, 672. (**D, E**) UV-vis absorption (left panels) and MALDI-TOF mass spectra (right panels) of purified recombinant Sfh5 sourced from *C. albicans* (Sfh5^CA^) and *C. glabrata* (Sfh5^CG^). Spectral profiles of dithionite-treated versions of these proteins were red-shifted to 422 and 428 nm for Sfh5^CA^ and Sfh5^CG^, respectively. Total counts within the indicated m/z ranges were 1404 and 1739 for Sfh5^CA^ and Sfh5^CG^, respectively.](elife-57081-fig1){#fig1}

Several lines of evidence identify Sfh5 as a bona fide heme-binding protein. First, a tag-less version of Sfh5 expressed in *E. coli* showed similar Soret profiles \-- demonstrating that heme-binding by Sfh5 is not a His-tag artifact ([Figure 1C](#fig1){ref-type="fig"}; top left panel). Second, matrix-assisted laser desorption-ionization (MALDI) mass spectroscopy of recombinant His~6~-Sfh5 purified from bacteria, as well as of His-tagged Sfh5 purified directly from yeast, yielded iron-protoporphyrin IX signatures at an *m/z* = 616 ± 2 Da ([Figure 1C](#fig1){ref-type="fig"}; bottom panels). Third, the heme-binding property was conserved in Sfh5 orthologs from other fungal species -- including pathogenic fungi from the genus *Candida*. Purified recombinant Sfh5 orthologs of *Candida albicans* (Sfh5^CA^, orf 19.4897) and *Candida glabrata* (Sfh5^CG^, CAGL0I05940g) were reddish-brown, both *Candida* Sfh5 preparations exhibited obvious Soret profiles, and both preparations yielded iron-protoporphyrin IX signatures when interrogated by MALDI mass spectrometry ([Figure 1D,E](#fig1){ref-type="fig"}). Since all but one of the *Candida* Sfh5 proteins lack Cys residues, the Sfh5 heme is not coordinated by cysteine \-- thereby excluding P450-type heme centers or \[Fe-S\] cluster proteins.

Sfh5 crystal structure {#s2-2}
----------------------

Hydrodynamic analyses indicated that purified recombinant Sfh5 exists in a uniform oligomeric state calculated to be a dimer in solution ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}), and crystallization conditions were optimized so that brown, rod-shaped, diffraction-quality crystals appeared within three days of incubation ([Figure 2A](#fig2){ref-type="fig"}). The crystallographic symmetry was of the orthorhombic space group P4~3~2~1~2 (unit cell dimensions a = b = 205 Å, c = 68 Å) with a high solvent content of \~64% ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). As molecular replacement proved unsuitable for solving the Sfh5 structure, single-wavelength anomalous diffraction was used to exploit the iron anomalous signal at Cu Kα edge to obtain phase information. The final Sfh5 structure was refined to 2.9 Å resolution ([Table 1](#table1){ref-type="table"}; PDB ID 6W32). The crystal asymmetric unit (ASU) contained three molecules of Sfh5 with a single heme-Fe bound to each of the chains. The crystallized form appears to be monomeric. While two molecules in the ASU make relatively close contact, the third molecule lacks a contact partner when checked across the symmetry axis ([Figure 2B](#fig2){ref-type="fig"}). Assessment of the crystal contact interfaces by the PISA server (<https://www.ebi.ac.uk/pdbe/pisa/>) concluded that these crystal contacts are unlikely to support stable quaternary assemblies in solution. One chain in the asymmetric unit (chain B) exhibited well-ordered electron density and was built with high confidence and good stereo-chemistry. However, the electron densities of the N-terminal domain of the two other chains (chains A and C) were poorly defined. Thus, the model for chain B was used for all subsequent structural analyses.

![Sfh5 crystal structure.\
(**A**) Recombinant Sfh5 forms reddish brown rod-shaped crystals. Scale bar, 50 µm. (**B**) The asymmetric unit consists of three Sfh5 molecules and ribbon representations are colored by molecule. The bound heme is shown in ball and stick with carbon atoms colored in brown, oxygen -- in red, and nitrogen in blue. (**C**) Ribbon diagram of the Sfh5 showing α-helices, loops and 3~10~ turns in blue, and β-strands in red. A single non-covalently-bound heme *b* molecule is rendered in green with the brown sphere representing the heme iron. (**D**) The PtdIns binding substructure of Sec14-like PITPs is conserved in Sfh5. A PtdIns molecule was modeled into the closed Sfh5 structure by overlaying Sfh1::PtdIns crystal structure (PDB ID: 3B7N) onto the Sfh5 crystal structure. This binding model emphasizes the conserved interactions (dashed lines) between Sec14 family PtdIns-binding barcode residues of Sfh5 and elements of the PtdIns headgroup. The corresponding distances between PtdIns headgroup structural elements and side-chains of the barcode residues in this dock model are shown.](elife-57081-fig2){#fig2}

###### X-ray data collection and refinement statistics.

Parentheses indicate highest shell.

  Data Collection             Phasing data set        Refinement data set
  --------------------------- ----------------------- -----------------------
  Wavelength (Å)              1.55                    1.55
  Space group                 P4~3~2~1~2              P4~3~2~1~2
  a, b, c (Å)                 205.13, 205.13, 68.27   205.34, 205.34, 68.31
  α, β, γ (°)                 90, 90, 90              90, 90, 90
  Resolution (Å)              41--2.7 (2.8--2.7)      29.3--2.9 (3.06--2.9)
  *R~merge~*                  0.291 (1.736)           0.157 (2.22)
  *R~pim~*                    0.049 (0.545)           0.064 (0.881)
  *I/σI*                      13.5 (0.8)              10.2 (1.2)
  Completeness (%)            98.5 (85.3)             99.6 (100)
  Redundancy                  32.2 (9.1)              6.9 (7.0)
  CC~1/2~%                    0.996 (0.303)           0.996 (0.505)
  Refinement                                          
  Resolution (Å)              29.3--2.9               
  No. of Reflections:         61477                   
  *R~work~*                   0.23                    
  *R~free~*                   0.30                    
  No. of atoms                7169                    
  Protein                     7040                    
  Ligand                      129                     
  B-factors (Å^2^)                                    
  Protein                     79.3                    
  Ligands                                             
  R.M.S. deviations:          57                      
  Bond lengths, rmsd (Å)      0.01                    
  Bond angles, rmsd (°)       1.41                    
  Ramachandran plot                                   
  Ramachandran favored (%)    86                      
  Ramachandran allowed (%)    13                      
  Ramachandran outliers (%)   0.5                     

Sfh5 adopted a typical Sec14-fold comprised of eight α-helices, five β-strands, five short 3~10~ helices and a β-hairpin turn ([@bib59]; [@bib58]; [@bib55]). A tripod motif formed by helices A~1~, A~3~ and A~4~ characterized the N-terminal domain but, unlike Sec14, the loop connecting helices A~1~ and A~3~ (A~2~ and A~3~ in Sec14) was expanded to host a hairpin turn and another helix (A~2~; [Figure 2C](#fig2){ref-type="fig"}). As typically observed in Sec14-like PITPs, the internal cavity of Sfh5 was defined by a β-sheet floor with α helices A~5~-A~6~ forming one side. Helix A~7~, in conjunction with an extension loop, comprised the substructure that gates the cavity. The isostructural A~10~/T~4~ gating helices of Sfh1 and Sfh5 were positioned similarly across the opening to the internal cavity ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). By contrast, the Sfh5 helical gate was shifted by \~18 Å across the cavity opening relative to the position of this substructure in Sec14 \-- thereby describing a 'closed' Sfh5 conformer ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Again, in a strategy conserved across the Sec14-like PITP family, Sfh5 residue F~228~, located at the C-terminus of the KKFV gating element (KPFL in Sec14 and Sfh1), engaged K~192~ of the adjacent helix A~6~ in a cation-π interaction to stabilize the closed conformer. Hydrophobic interactions between V~229~ on the loop extending from helix A~7~, and I~195~ of helix A~6~, stabilized this closed conformation. Further ramifications of the K~192~-F~228~ interaction will be detailed below.

In Sec14 and Sfh1, the conformational dynamics of the helical gate are coupled to a switch module (G-module) that operates via rearrangement of multiple H-bonds between distinct substructures to open and close the helical gate ([@bib56]). A prominent component of the switch element is a string motif that wraps around the back of the protein molecule and is characterized by a series of short 3~10~-helices. This structural motif is conserved in Sfh5 ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Although no bound phospholipid was detected in the Sfh5 ligand-binding pocket, and the pocket was occupied with heme, the structural elements that comprise the PtdIns-binding substructure in other Sec14-like PITPs are conserved in Sfh5 ([Figure 2D](#fig2){ref-type="fig"}).

Coordination environment of Sfh5-bound heme {#s2-3}
-------------------------------------------

Although the final refined Sfh5 structure had poor electron densities for several unstructured regions, especially in chains A and C, the *2Fo-Fc* electron density was clear and well defined for the heme-binding region of all three chains. Bound heme was not visible in the surface render of the closed Sfh5 conformer ([Figure 3A](#fig3){ref-type="fig"}; left panel). The extent to which heme was buried in the 'closed' Sfh5 conformer was quantified by calculating its solvent-exposed surface area. Only \~8 Å^2^ of the heme surface area was solvent exposed \-- as opposed to 835 Å^2^ for free heme. The deep sequestration of bound heme in the Sfh5 internal cavity was visualized in a slice representation of the closed Sfh5 conformer ([Figure 3A](#fig3){ref-type="fig"}; right panel). The plane of the heme *b* porphyrin ring ran parallel to helix A~6~ and to β-strands B~3~-B~5~ which collectively form the β-sheet floor of the binding cavity. In that configuration, heme *b* exhibited twenty-five van der Waals interactions with amino acid side chains of the residues that line the cavity, including residues F~138~, F~144~, V~178~, I~187~, I~195~, F~211~, V~212~, F~218~, I~225~, V~229~, and F~237~ ([Figure 3B](#fig3){ref-type="fig"}). In addition, F~211~, Y~128~ and Y~175~ formed π-π stacking interactions with the pyrrole groups of the heme porphyrin ring.

![Coordination environment of Sfh5-bound heme.\
(**A**) Left panel shows the surface rendering of Sfh5 in grey. Right panel shows surface view of Sfh5 clipped to expose the buried heme rendered in yellow ball and stick with protein secondary structure elements depicted in cartoon ribbon. (**B**) Heme bound to chain B of the Sfh5 crystal structure. The 2Fo-Fc electron density map for heme contoured at 1.5 σ is displayed as blue mesh. Residues engaged in van der Waals contacts with heme are shown as gray spheres. The side-chains of residues interacting with the propionyl groups of heme (K~209~ and R~148~) are presented as red dots. (**C**) Left panel: Sfh5 residues that bind heme are shown including the Fe-coordinating residues Y~175~ and H~173~. Dashed lines identify the inter-atomic distances between the indicated Sfh5 residues and cognate components of heme. Polder omit electron density map for heme is shown as green mesh ([@bib43]), contoured at 2.5 σ. Right panel: Lateral view of the 2Fo-Fc map showing electron density associated with residues coordinating the heme iron center (contoured at 1.5σ). (**D**) Surface view of Sfh5 clipped to display the ligand-binding cavity. Bound heme (shown in ball and stick and colored by the element with carbons in gold) resides deep inside the cavity. Heme-coordinating residues H~173~ and Y~175~ are displayed in ball and stick mode and colored by element with carbons in light gray. Indicated access to the vacant heme coordination site from solvent is potentially controlled by conformational transitions of the K~188~ and K~192~ side chains (labeled as substrate channel, entrance displayed in ball and stick render and colored by element with carbons in green), and the side-chains of residues L~224~, I~225~ and F~228~ (colored by element with carbons in yellow). The surface contributed by the side chains of residues K~188~ and K~192~ is colored in green. Access channel for lipid to the internal cavity of other Sec14-like PITPs is also indicated.\
Figure 3---source data 1.Fungal Sfh5 orthologs.The *S. cerevisiae* Sfh5 primary sequence was used as query in a Uniprot BLAST search to identify orthologs across the fungal kingdom. Initial sequence alignments were performed using ClustalW and followed by a Sfh5 structure guided alignment of the sequences using ESCRIPT. Sequences from *C. glabrata*, *C. albicans*, *C. tropicalis*, *C. auris*, *A. nidulans*, *A. oryzae*, *N. crassa*, *C. neoformans* and *Y. lipolytica* were aligned. Conserved residues are highlighted in red. At bottom are identified the Sfh5 residues that: (**i**) correspond to the PtdIns-binding barcode common to Sec14-like PITPs (▲), (**ii**) that are engaged in van der Waals interactions with heme or π-π stacking interactions with the pyrrole groups of the porphyrin ring (●), (**iii**) engage in electrostatic or H-bond interactions with heme \-- that is. the heme-binding barcode (♦) and (**iv**) conserved residues Lys~188~ and Lys~192~ that are poised to gate access to the empty pocket distal to the heme iron (arrows). Secondary structure elements as determined from the Sfh5 crystal structure are identified at top.](elife-57081-fig3){#fig3}

Heme *b* binding within the Sfh5 internal cavity exhibited two notable characteristics. First, the porphyrin conformations within the each of the three monomers (identified as chains A, B and C) were largely planar as far as could be determined at the resolution level of the structure. Second, the heme *b* coordination mechanism was unusual. Bound heme-Fe was in close proximity (2.3 Å) to the hydroxyl group of residue Y~175~ ([Figure 3C](#fig3){ref-type="fig"}; left panel), and tyrosine coordination was consistent with the results of safranin T dye-reduction assays which estimated an unusually low thermodynamic reduction potential for Sfh5 heme (−330 ± 3 mV vs normal hydrogen electrode). The Y~175~ hydroxyl group also engaged the Nε2-tautomer of the proximal H~173~ via a hydrogen bond interaction ([Figure 3C](#fig3){ref-type="fig"}; left panel). Residue H~173~ was positioned orthogonal to the heme plane and was poised to form a salt bridge between the Nδ1-tautomer and one of the heme propionate moieties. Moreover, a chain of H-bond and polar interactions was evident between the bound Fe, Y~175~ and H~173~, and extended from the Fe center to a propionate side chain of bound heme in contact with the porphyrin ring. The heme propionate groups also engaged in H-bonding and acid/base interactions with Sfh5 residues Y~128~, R~148~ and K~209~. Moreover, the S~191~ side-chain was in H-bond contact with the nitrogen of the heme pyrrole ring ([Figure 3C](#fig3){ref-type="fig"}; left panel). We note this configuration for S~191~ was on display in the chain B structure whereas rotamers where the S~191~ side-chain was flipped 180° away from the heme center were more consistent with the refined chain A and chain C structures. Alignment of Sfh5 homologs from multiple fungal species indicate residues Y~128~, R~148~, H~173~, Y~175~, and K~209~ are invariant, and that multiple other heme-coordinating residues (including S~191~) are also highly conserved \-- thereby defining a barcode for heme binding by Sec14-like proteins of the Sfh5 clade ([Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}). This configuration forms an extensive electronic system ([Figure 3C](#fig3){ref-type="fig"}; right panel).

Only two amino acid side chains (S~191~ and I~225~) reside within a 5 Å radius on the distal side of the Fe \-- reporting the absence of a sixth coordinating ligand and establishing that bound Fe is penta-coordinate. That vacant coordination site on the distal side of the Fe represents a candidate substrate binding pocket positioned close to the Sfh5 protein surface and to which access from solvent is occluded by the side chains of K~188~ and K~192~ of helix A~6~ on one side and residues L~224~, I~225~ of helix A~7~ and F~228~ on the loop connecting helix A~7~ and 3~10~-helix T~4~, on the other ([Figure 3D](#fig3){ref-type="fig"}). As discussed above, K~192~ and F~228~ engage in a cation-π interaction that stabilizes the closed conformation of the Sfh5 helical gate whose isostructural elements control access to the lipid binding cavity in Sec14 and other Sec14-like PITPs. This arrangement suggests a mechanism where rotamer rearrangements of these side chains, and/or conformational transitions of the A~7~ helix, gate substrate access into the vacant heme coordination site. Notably, K~188~ and K~192~ are absolutely conserved across the Sfh5 clade, whereas the F~228~ is highly conserved. In cases where the F~228~ cognate is a valine, it is the K~188~ cognate that is projected to engage in a cation-π interaction with a phenylalanine that replaces the cognate L~224~ ([Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}).

Roles of residues Y~175~ and H~173~ in heme binding and Fe-center chemistry {#s2-4}
---------------------------------------------------------------------------

Heme-binding tyrosines can be stabilized by adjacent ionizable residues that enhance the tyrosinate character and strengthen the Tyr O-Fe bond ([@bib53]; [@bib60]; [@bib13]). The Sfh5 structure suggested that the H~173~ Nδ1 proton acts as an H-bond donor to Y~175~ -- thus transferring negative charge from the tyrosinate ion to the H~173~ imidazole ring and modulating strength of the Y~175~-Fe interaction. To test this possibility, a series of Sfh5 Y~175~ and H~173~ missense mutants was generated and the consequences on heme binding characterized. As demonstrated in other experiments described below, the relevant Sfh5 heme-binding mutants were all properly folded proteins.

That heme binding was compromised in specific mutants was readily apparent from the colors of the purified recombinant proteins ([Figure 4A](#fig4){ref-type="fig"}). Such deficits were quantified by the decline in Soret peak intensities and heme content as determined by pyridine hemochromagen assays and ICP-MS analyses of the mutant proteins ([Figure 4B](#fig4){ref-type="fig"}, [Supplementary file 1](#supp1){ref-type="supplementary-material"}). Substitution of the axial Y~175~ by non-polar residues (i.e. Sfh5^Y175A^ and Sfh^Y175F^) completely abrogated heme binding whereas the Sfh5^Y175H^ mutant largely retained the ability to bind heme \-- revealing the necessity of a polar axial ligand for efficient heme binding ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). The Sfh5^H173A^ variant showed an \~50% reduction in heme binding, while the Sfh5^H173Y^ variant, unlike Sfh5^H173A^, purified with heme loaded at levels comparable to Sfh5 \-- further highlighting the role of the amino acid co-axial to residue Y~175~ in stabilizing the critical Y~175~-Fe interaction. The Soret maxima for Sfh5^H173Y^ shifted to 402 nm as compared to 404 nm for wild-type Sfh5 with no appreciable change upon exposure to excess dithionite ([Figure 4C](#fig4){ref-type="fig"}). By contrast, the Soret maximum of Sfh5^Y175H^ was centered at 407 nm and red-shifted to 430 nm upon reduction of the protein with dithionite \-- suggesting the heme in this mutant was in the oxidized Fe^3+^ state ([Figure 4D](#fig4){ref-type="fig"}). These results demonstrated that the Y~175~ interaction with Fe was essential for stabilizing heme binding, and that H~173~ played an important role in enhancing Lewis basicity of the Y~175~ hydroxyl in its interaction with heme.

![Roles of Sfh5 residues Y~175~ and H~173~ in heme binding and Fe-center chemistry.\
(**A**) The color intensities of solutions (30 μM) of purified recombinant Sfh5 (left), Sfh5^H173A^ (middle) and Sfh5^Y175F^ (right) are compared. (**B**) UV-vis absorption spectra of Sfh5, Sfh5^H173A^, Sfh5^Y175A^ and Sfh5^Y175F^ are shown. The protein concentrations were fixed at 30 μM. (**C, D**) UV-vis spectra of Sfh5^H173Y^ and Sfh5^Y175H^ are shown, respectively. Spectra obtained after reduction of sample with dithionite are in red. Sfh5^H173Y^ did not undergo a spectral shift upon reduction.](elife-57081-fig4){#fig4}

Biophysical properties of the Sfh5 Fe-center {#s2-5}
--------------------------------------------

The 10 K X-band electron paramagnetic resonance (EPR) spectrum of oxidized wild-type Sfh5 exhibited an axial signal with g~⊥~=5.83 and g~‖~=2.00. This spectrum is typical of high-spin S = 5/2 Fe^3+^ heme centers with the rhombicity parameter E/D ≈ 0 ([Figure 5A](#fig5){ref-type="fig"}; [@bib24]; [@bib3]). No signals reflecting low-spin Fe^3+^ hemes were detected. The Fe^3+^ heme assignment was further supported by the loss of the EPR signal upon reduction with dithionite. Taken together, these data confirm that the heme prosthetic group is redox-active and that the oxidized Fe^3+^ state is a high-spin penta-coordinate with a vacant axial site. Moreover, the data show that the reduced state is EPR-silent -- consistent with reduction to the Fe^2+^ state.

![Electronic properties of the Sfh5 Fe-center.\
(**A**) EPR spectra of purified Sfh5 before (-) and after dithionite treatment (+). (**B**) UV-visible absorption spectrum of purified (oxidized) Sfh5 without and with treatment with potassium ferricyanide as source of cyanide ion (CN^-^) ([@bib11]). Inset shows the difference spectrum between the two conditions and highlights a significant red shift in the Soret maximum induced by CN^-^. (**C**) Purified Sfh5 was first reduced with excess dithionite and spectra were taken before and after incubation in the presence of CN^-^. Inset indicates the difference spectrum between the two conditions and shows no appreciable shift in the Soret maximum. (**D**) UV-vis spectra before and after incubation of purified Sfh5 with carbon monoxide (CO) gas are shown. Inset indicates the difference spectrum between the two conditions and shows no shift in the Soret maximum in the presence of CO. (**E**) UV-vis spectra of purified Sfh5 reduced with dithionite and incubated in the presence of CO. Inset, difference spectra as indicated. (**F**) EPR spectra of purified Sfh5, Sfh5^H173A^, Sfh5^H173Y^, Sfh5^Y175H^, and Sfh5^Y175F^ are shown. Protein samples were normalized by concentration (150 μM).](elife-57081-fig5){#fig5}

The ability of the vacant coordination site to bind diatomic molecules was interrogated. In one set of experiments, exposure of oxidized Fe^3+^ Sfh5 to a molar excess of potassium cyanide (KCN) induced a marked red-shift of the Soret peak from 404 to 417 nm ([Figure 5B](#fig5){ref-type="fig"}). Heme titration experiments with CN^-^ reported a 1:1 binding stoichiometry \-- indicating one bound CN^-^ per Fe^3+^ heme center ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Cyanide ions did not appear to coordinate the reduced heme center as no shift in the Soret band was observed when Sfh5 was first reduced with excess sodium dithionite prior to exposure to CN^-^ ([Figure 5C](#fig5){ref-type="fig"}).

In a second set of experiments, oxidized Sfh5 was exposed to a CO atmosphere. This exposure failed to induce a spectral shift in the Soret profile ([Figure 5D](#fig5){ref-type="fig"}) \-- suggesting that CO did not bind to Sfh5 Fe^3+^ heme. However, exposure of dithionite-reduced Sfh5 to CO resulted in a blue shift of the Soret maximum from 426 to 416 nm ([Figure 5E](#fig5){ref-type="fig"}) -- demonstrating CO binding to reduced Sfh5 and suggesting formation of a low-spin Fe^2+^ hemoprotein carbonyl complex. Analyses of the α-bands under those conditions indicated CO bound stoichiometrically to reduced heme (100% of reduced Sfh5 bound CO; [Figure 5E](#fig5){ref-type="fig"}, inset). The collective results indicate that the vacant axial site of Sfh5 heme can coordinate small exogenous ligands with CN^-^ and CO binding the Fe^3+^ and Fe^2+^ state, respectively.

The effects of Y~175~ and H~173~ on Sfh5 heme electronics were also assessed. The EPR signal exhibited by the Sfh5^H173A^ mutant showed features similar to those of wild-type Sfh5, suggesting that the mutant heme center was also high spin Fe^3+^, albeit with a rhombic parameter (E/D ≈ 0.02) that is more typical of tyrosine-ligated five coordinate (5 c) hemes ([@bib2]). A rhombic g-tensor was evident in the spectrum of Sfh5^H173Y^, whereas Sfh5^Y175H^ presented spectral features most similar to those of wild-type Sfh5 ([Figure 5F](#fig5){ref-type="fig"}). Taken together, these data indicate that the Fe-tyrosine bond is subject to modulation by the co-axial H~173~.

As is the case with other heme-containing proteins, Sfh5 exhibited pseudo-peroxidase activity when pyrogallol was offered as a substrate and its oxidation to purpugallin was followed (see Materials and Methods). The observed low-level activity (relative to a horseradish peroxidase control) was abolished in Sfh5^H173A^, but was stimulated 4-fold in Sfh5^Y175H^ ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). While catalases are heme proteins with tyrosine axial ligands, purified Sfh5 exhibited no measurable catalase activity in vitro.

Sfh5 heme center exhibits two magnetic states {#s2-6}
---------------------------------------------

The electronic properties of the Sfh5 heme center were investigated in greater detail using Mössbauer spectroscopy. Simulation of low-temperature, low-field (5 K, 0.05 T) spectra of oxidized ^57^Fe-enriched wild-type Sfh5 ([Figure 6A](#fig6){ref-type="fig"}) required consideration of two magnetic states. The solid red line describes a simulation assuming two S = 5/2 Fe^III^ heme states that we term LA (Large A) and SA (small A). The LA state exhibited larger average hyperfine couplings (A-values) whereas the SA state was characterized by smaller A-values ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). The fitting parameters were similar to those previously obtained for high-spin Fe^3+^ hemes with phenolate coordination ([@bib12]).

![Sfh5 heme center exhibits two magnetic states.\
Mössbauer spectra were collected at low-temperature (5 K) and field (0.05 T). (**A**) Spectrum of Sfh5 sample prepared at pH 7. The red line is a composite simulation with 63% Fe^III^~LA~ site and 37% Fe^III^~SA~ site. (**B**) Spectrum of an independent sample of Sfh5 prepared at pH 8. (**C**) Spectrum of the sample of Sfh5 in (**B**) reduced with sodium dithionite. The simulation in B was used to remove 60% of the overall spectral intensity in C. (**D**) Spectrum of Sfh5^H173A^100% Fe^III^~LA~ site. In all spectra, the field was applied parallel to the gamma radiation.](elife-57081-fig6){#fig6}

The six independently generated Sfh5 preparations analyzed exhibited similar spectra but required somewhat different relative intensity ratios for the two magnetic states from preparation to preparation. The high-field (6 T) spectrum of one ^57^Fe-enriched Sfh5 preparation could also be fitted using the same two-state model ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). The magnetic hyperfine interactions associated with the LA state were partially collapsed by warming the sample to 150 K whereas those for the SA state were not (data not shown). The Mössbauer spectrum of another Sfh5 preparation was dominated by the SA state ([Figure 6B](#fig6){ref-type="fig"}). After treatment with dithionite, the ^57^Fe-enriched Sfh5 exhibited a quadrupole doublet typical of high-spin Fe^2+^ ([Figure 6C](#fig6){ref-type="fig"}), confirming the Fe^3+/2+^ redox activity of Sfh5 heme. By contrast, simulating the Mössbauer spectrum of ^57^Fe-enriched Sfh5^H173A^ required only consideration of the LA state ([Figure 6D](#fig6){ref-type="fig"}). Moreover, the collapsed LA state recorded for ^57^Fe-enriched Sfh5 fit to a quadrupole doublet with the same isomer shift δ and quadrupole splitting ΔE~Q~ used to simulate the Sfh5^H173A^ spectrum. These findings further reinforce the case for a two magnetic state model for the Sfh5 heme center.

Incompatibility of high affinity Sfh5 heme-binding with PtdIns binding/exchange {#s2-7}
-------------------------------------------------------------------------------

A distinguishing property of Sfh5 is that, among the yeast Sec14-like PITPs, this protein exhibits only marginal PtdIns-exchange activity in vitro and is incapable of significantly stimulating PtdIns 4-OH kinase activity in vivo \-- as evidenced by the fact that its high-level expression is unable to rescue growth of cells depleted of Sec14 activity ([@bib41]). These properties are evident even though Sfh5 conserves the PtdIns-binding barcode that is the cardinal signature of the Sec14 superfamily ([@bib58]; [@bib8]). We therefore considered the possibility that Sfh5 does not function as a PITP per se, and that heme is not an exchangeable second ligand. This property would be unique to Sfh5 as other members of the Sec14-like PITP family all have the capacity to host an exchangeable second lipid ([@bib63]).

Based on the fact that Sfh5 exhibits an intact PtdIns-binding barcode, we hypothesized that abrogation of heme-binding might reactivate PtdIns- exchange activity in Sfh5. This prediction was independently examined using both in vitro and in vivo approaches. First, the PtdIns-exchange activities of purified Sfh5 and Sfh5 heme-binding mutants were tested using an assay that monitors transfer of \[^3^H\]-PtdIns from rat liver microsomes to PtdCho liposomes in vitro. Whereas wild-type Sfh5 showed little activity, as previously reported ([@bib41]), the heme-less Sfh5^Y175F^ variant exhibited enhanced activity relative to wild-type \-- the specific activity of Sfh5^Y175F^ was \~70% of Sec14 relative to \~10% for Sfh5. The Sfh5^H173A^ mutant with reduced heme-binding capacity also showed enhanced activity \-- one that was intermediate between those of wild-type Sfh5 and Sfh5^Y175F^ ([Figure 7A](#fig7){ref-type="fig"}). These data indicated that Sfh5 PtdIns-transfer activity is inversely proportional to heme-binding affinity, and that these heme-binding mutants are well-folded proteins in functional conformations. As expected, the purified Sfh5^Y68A,Y175F^ and Sfh5^Y175,E204VF^ variants with compromised PtdIns-binding barcodes were significantly defective in PtdIns-transfer activity in vitro relative to the Sfh5^Y175F^ control.

![Incompatibility of high affinity Sfh5 heme-binding with PtdIns binding.\
(**A**) In vitro \[^3^H\]-PtdIns transfer assays were performed with purified recombinant Sfh5, Sfh5^H173A^ and Sfh5^Y175F^ in a titration series where protein inputs were increased in steps of two-fold (5, 10, 20, 40 µg). The total radiolabeled input for each assay varied between 8377 to 12,070 cpm, and background ranged between 150--575 cpm. The transfer values represent the mean of triplicate assay determinations from at least two independent experiments. (**B**) Resuscitation of PITP activity in heme-deficient Sfh5 mutants in vivo. Left panel: A *sec14-1^ts^* strain was transformed with episomal YEp(*URA3*) plasmids that drive constitutive ectopic expression of *SEC14*, *SFH5* or *sfh5^Y175F^* from the powerful *PMA1* promoter. The transformants were spotted in 10-fold dilution series onto YPD plates and incubated at the indicated temperatures for 48 hr before imaging. Growth at 37°C reports rescue of growth defects associated with the *sec14-1^ts^* allele at this normally restrictive temperature. Right panel: A *sec14Δ ade2 ade3*/YEp(*SEC14, LEU2, ADE3*) strain was transformed with the indicated YEp(*URA3*) expression plasmids described in (**B**). Transformants were again spotted in dilution series onto YPD plate as above. Under those conditions, all nutrient selections are relieved and loss of the normally essential YEp(*SEC14, LEU2, ADE3*) plasmid (which has the dual properties of covering the lethal *sec14Δ* allele and also the *ade3* allele which coverts colony color of *ade2* cells from red to white) can be monitored. Appearance of white colonies that are phenotypically Leu auxotrophs signifies loss of the parental YEp(*SEC14, LEU2, ADE3*) plasmid on the basis of the YEp(*URA3*) plasmid driving expression of a functional PITP. Uniformly red colonies report the YEp(*URA3*) expression plasmid does not drive production of a functional PITP with the capacity to provide Sec14-like functions to Sec14-deficient cells. YEp(*SEC14*) serves as positive control in these experiments. (**C**) PITP activity is not resuscitated in Sfh5 expressed in yeast cells devoid of heme. Isogenic *hem1Δ* and *hem1Δ sec14-1^ts^* strains deficient in α-aminolevulenic acid (ALA) synthesis were transformed with YEp(*URA3*) plasmid as mock control or for expression of *SEC14*, *SFH5* or *sfh5^Y175F^* as indicated. Transformants were selected on a minimal media plate without uracil and supplemented with 250 µM ALA. After depleting cells for residual heme by growth in ergosterol-containing medium (added to a 20 mg/l final concentration from a 0.2% stock solution in 1:1 ethanol: Tween 80), cells were spotted onto YPD solid medium or onto YPD solid medium supplemented with ALA (250 µM) to rescue the *hem1Δ* deficiency, or onto YPD solid medium supplemented with 50 µM ergosterol/Tween 80 (Erg/Tween80) to rescue the heme deficiency without permitting heme synthesis. The cells were incubated for 72 hr at the indicated temperatures prior to imaging. The *hem1Δ* control cells grow under all conditions that either rescue heme synthesis (+ALA) or provide exogenous ergosterol whose synthesis is the sole essential heme-dependent activity in cells cultured under these conditions. Growth of the *hem1Δ sec14-1^ts^* mutant at the restrictive temperature of 37C was not rescued by enhanced expression of WT Sfh5 under heme-less conditions (i.e. on YPD supplemented with Erg/Tween80). Expression of *SEC14* or the *sfh5^Y175F^* heme-binding mutant served as additional positive controls.](elife-57081-fig7){#fig7}

Second, the in vitro data were reinforced by two sets of in vivo results. Whereas high-level expression of wild-type Sfh5 was unable to rescue *sec14-1^ts^* associated growth defects when the test strain was challenged at the restrictive temperature of 37°C, Sfh5^Y175F^ expression supported a robust rescue of the growth defect ([Figure 7B](#fig7){ref-type="fig"}, left panel). Similar data were forthcoming from plasmid-shuffle assays where the abilities of Sfh5 and its variants to bypass the essential cellular requirement for Sec14 activity, when expressed at high levels, were examined ([Figure 7B](#fig7){ref-type="fig"}, right panel). Whereas high-level expression of Sfh5^Y175F^ was capable of supporting viability of *sec14Δ* segregants, expression of wild-type Sfh5 was not able to do so.

As ergosterol synthesis is the sole 'essential' heme-dependent activity in yeast grown with glucose as sole carbon source, we tested whether resuscitation of PtdIns-exchange activity of wild-type Sfh5 was recapitulated when Sfh5 was expressed in heme-less *hem1Δ* yeast mutants cultured in the presence of ergosterol. Unlike the case for the Sfh5^Y175^ mutant, enhanced expression of WT Sfh5 was unable to rescue growth of the in *hem1Δ sec14-1^ts^* mutant at 37 °C ([Figure 7C](#fig7){ref-type="fig"}). That is, wild-type Sfh5 produced in a heme-free cellular context still failed to exhibit PITP activity. Taken in aggregate, these data report that Sfh5 does not function as a PtdIns/heme-exchange protein in vitro or in vivo.

Another unforeseen result came from reciprocal experiments where PtdIns-binding deficits were introduced into Sfh5 mutants strongly defective in heme-binding. In those experiments, the Y~68~A substitution that compromises the Sfh5 PtdIns-binding barcode was incorporated into the heme-less Sfh5^Y175F^ context. Surprisingly, the Sfh5^Y68A,Y175F^ double mutant protein showed unambiguous resuscitation of low level heme binding. That is, Sfh5^Y68A,Y175F^ showed a weak, yet distinct, Soret peak at 413 nm ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}), and a weak EPR signature of high spin Fe^3+^ heme, while Sfh5^Y175F^ did not ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). Thus, alterations in the Sfh5 PtdIns-binding substructure defects can partially relieve heme-binding defects -- even though the structural elements that coordinate PtdIns headgroup binding and heme-binding are physically distinct. There is specificity to this effect as the E~204~V PtdIns-binding barcode mutation, which effectively abolishes PtdIns-binding by Sfh5, did not resuscitate measurable heme-binding in the Sfh5^Y175F^ context (data not shown).

Sfh5 heme is not exchangeable with an apo-myoglobin acceptor {#s2-8}
------------------------------------------------------------

As Sfh5 exhibits feeble PtdIns/heme exchange activity in vitro, and it does not exhibit the properties of a canonical PITP in vivo, we considered the possibility that Sfh5 donates bound heme to a suitable acceptor apo-protein. To test this hypothesis, an in vitro assay was developed where Sfh5 served as heme donor and apo-myoglobin was incorporated as an avid heme acceptor. We took advantage of the pseudo-peroxidase activities of myoglobin and of heme-bound Sfh5 to monitor transfer of heme from Sfh5 to apo-myoglobin. Although apo-myoglobin readily bound free heme presented as hemin, no transfer of heme between Sfh5 donor and apo-myoglobin acceptor was recorded in this assay regime \-- even after prolonged incubation ([Figure 8](#fig8){ref-type="fig"}). Reduction of Sfh5 heme with dithionite was ineffective in promoting heme transfer to apo-myoglobin (data not shown). These data indicate that Sfh5 binds heme with high affinity, and lend further support to the concept that Sfh5-bound heme is not an exchangeable ligand.

![Sfh5 does not donate bound heme to an efficient heme scavenger.\
Top panels: Coomassie-stained SDS-PAGE gel images of Sfh5, myoglobin and apo-myoglobin proteins run individually and mixtures of hemin/apo-myoglobin and Sfh5/apo-myoglobin (as indicated) that were pre-incubated for the indicated times. The proteins migrate with the expected masses of 35.7 kDa for the Sfh5 monomer and 18 kDa for myoglobin/apo-myoglobin. Bottom panels show corresponding chemiluminescent images of the nitrocellulose membranes onto which the proteins from duplicate SDS-PAGE gels were transferred and probed by visualizing pseudo-peroxidase activity in situ. Whereas apo-myoglobin avidly scavenged hemin from the medium, no measurable transfer of heme from Sfh5 to apo-myoglobin was detected.](elife-57081-fig8){#fig8}

Sensitivity of Sfh5-deficient cells to an organic oxidant {#s2-9}
---------------------------------------------------------

The biological function of Sfh5 is enigmatic as it is expressed at very low levels, the subcellular localization of the endogenous protein is unknown, and its function is non-essential for yeast viability ([@bib41]). Indeed, there is unusually little information regarding its function that can be gleaned from genetic or physical interaction databases. Consistent with that, *sfh5Δ* mutants were not compromised for growth on non-fermentable carbon sources ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}) -- indicating Sfh5 does not play a major cellular role in either regulating heme homeostasis or in loading of apo-proteins with heme. To assess whether Sfh5 plays some role in either Fe or heme uptake, *sfh5Δ* strains were cultured in media containing the Fe-chelator bathophenanthroline to induce an Fe-limiting environment. Neither functional ablation nor overexpression of Sfh5 had any significant effect on cell growth under those conditions ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). To investigate a hemin uptake activity for Sfh5, we took advantage of a *hem1Δ* (δ-aminolevulenate synthase-deficient) yeast mutant unable to synthesize heme. This mutant requires exogenous δ-aminolevulenic acid for survival and, as hemin is not efficiently transported into yeast cells, low concentrations of hemin fail to restore viability to *hem1Δ* cells ([@bib71]). Whereas expression of the *C. elegans* heme transporter Hrg4 in *hem1Δ* yeast rescued growth in media supplemented with low concentrations of hemin, overexpression of Sfh5 did not -- contraindicating a heme-transport function for Sfh5 ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}).

The collective data suggest that Sfh5 function is not essential under the conditions typically interrogated in the laboratory. However, mining of a comprehensive HIPHOP chemogenomics database identified a significant and specific sensitivity of Sfh5-deficient yeast cells to challenge with the synthetic organosulfur dithiolethione oltipraz. That phenotype was interrogated in the context of a diploid library of yeast deletion mutants where each essential yeast gene was represented in a heterozygous +/*Δ* arrangement while each non-essential gene was represented in a homozygous *Δ*/*Δ* arrangement ([@bib39]). Oltipraz induces superoxide radical formation and consequently triggers a general 'heme-requiring' response in yeast ([@bib33]; [@bib64]). This signature is manifested by the fact that heterozygous diploid yeast strains reduced for heme-biosynthetic capacity (*+/hem1Δ*, *+/hem2Δ*, *+/hem3Δ*, and *+/hem12Δ*) score as having an enhanced sensitivity to oltipraz ([Figure 8---figure supplement 2](#fig8s2){ref-type="fig"}).

When nonessential genes are analyzed in homozygous null mutant backgrounds, mutants with diminished capacities for scavenging reactive oxygen species (e.g. mutants functionally ablated for Sod1 superoxide dismutase activity and the Sod1 copper chaperone Ccs1) also score as hypersensitive to oltipraz -- as do *sfh5Δ* cells ([Figure 8---figure supplement 2](#fig8s2){ref-type="fig"}). None of the other five yeast Sec14-like PITPs are included in this chemogenomic signature, although enrichment of mutants defective in lobe B elements of the COG complex that regulates protein trafficking through the Golgi complex is notable. When the *sfh5Δ* chemogenomic profile and the ability of Sfh5 to bind heme are considered in aggregate, these properties converge on a hypothesis that Sfh5 functions in some aspect of redox control, and/or regulation of heme homeostasis, under stress conditions induced by exposure to organic oxidants.

Discussion {#s3}
==========

Herein, we describe the structural, biophysical and bioinorganic properties of Sfh5 -- an atypical Sec14-like protein. We report that Sfh5 is a penta-coordinate high spin Fe^3+^ heme-binding protein with unusual heme-binding and heme Fe-coordination properties. These describe a complex electronic system that is, to our knowledge, unique. As such, Sfh5 is the prototype of a new class of hemoproteins conserved across the fungal kingdom. In contrast to the known priming lipids of other Sec14-like PITPs, heme is not an exchangeable ligand for Sfh5, and the feeble PtdIns-exchange activity of Sfh5 is strongly enhanced in heme-binding mutants -- indicating Sfh5 is not designed to function as a bona fide PITP in vivo. While Sfh5 is non-essential for yeast viability under all conditions tested thus far, chemogenomic analyses suggest Sfh5 participates in stress responses to specific (albeit as yet unidentified) environmental organic oxidants. The collective data offer a powerful example of how evolution has used the Sec14-fold as a versatile scaffold for accommodating the binding of a wide variety of ligands, not only lipids, for the purpose of regulating diverse sets of cellular activities.

Sfh5 is a novel heme-binding protein {#s3-1}
------------------------------------

Solutions of purified Sfh5 are strikingly reddish-brown in color and this property reflects the fact that Sfh5 contains bound Fe. Soret signatures of purified Sfh5 are consistent with a non-covalently bound heme *b*-Fe complex. The physiological relevance of heme binding is amply demonstrated by the fact that Sfh5 purified from yeast contains non-covalently bound heme, and that purified recombinant Sfh5 orthologs derived from divergent fungal species similarly exhibit Soret profiles diagnostic of bound heme *b*-Fe. Moreover, the accessibility of Sfh5 heme to exogenous ligands such as CN^-^ and CO indicates a redox-active heme center with an open and available axial coordination site. The heme-bound Sfh5 structure presents a typical Sec14-fold consisting of an N-terminal tripod domain, and a C-terminal domain that forms the 'lipid-binding' pocket of Sfh5 ([@bib59]; [@bib58]). Consistent with the ICP-MS and Soret data, a single non-covalently bound heme *b*-Fe complex is visualized per Sfh5 monomer, and bound heme is sequestered deep within the 'lipid-binding' cavity.

Structural description of the Sfh5 heme center {#s3-2}
----------------------------------------------

A unique feature of the Sfh5 heme center is a complex electronic system where Fe is coordinated by Y~175~ in conjunction with the co-axial H~173~. This system incorporates three aromatic ring systems (the Y~175~ benzyl ring, the H~173~ imidazole, porphyrin) and open-shell iron d-orbitals that indicate extensive delocalization. How this unique structure operates poses an open question. That Fe- and heme-coordinating residues are highly conserved amongst the fungal Sfh5 orthologs reinforces our conclusion that these orthologs represent heme-binding proteins, and predicts that they also share the novel integrated electronic system defined by Sfh5. Moreover, the structural information identifies a heme-binding barcode for this class of Sec14-like proteins.

The absence of a sixth coordinating ligand for the Fe was evident from the structure -- confirming Sfh5 heme represents a penta-coordinate system. The vacant site can be occupied by diatomic molecules bound by Sfh5, and is the probable binding site for other potential Sfh5 ligands. The structure also suggests that entry into this vacant coordination site is likely gated by the side chains of two invariant residues of the Sfh5 clade (K~188~ and K~192~) and possibly conformational transitions of a gating helix analogous to that described for other Sec14-like PITPs. Interestingly, only \~4% of known hemoproteins exhibit Tyr as an axial ligand, and the majority of those that are penta-coordinate are catalases ([@bib42]). However, Sfh5 shows no measurable catalase activity \-- consistent with the absence of polar side chains near the sixth coordination site capable of stabilizing the oxo-ferryl intermediate of the catalase reaction. These collective results reinforce the structural and biophysical novelty of this site in Sfh5.

Magnetic properties of the Sfh5 heme center {#s3-3}
-------------------------------------------

EPR and Mössbauer analyses demonstrate Sfh5 contains a high-spin S = 5/2 Fe ^3+^ heme center, and both the EPR and Mössbauer signatures are typical of high-spin hemes. The electronics of the heme center are responsive to substitution of the co-axial H~173~ with Ala or Tyr, or substitution of Y~175~ with His, in a manner consistent with H~173~ status modulating the Y~175~-Fe interaction. Presumably, this modulation is achieved by stabilization of the Fe-coordinating tyrosinate ion. Mössbauer analyses identify two discrete magnetic states for the Sfh5 heme center, and one state is lost in the Sfh5^H173A^ mutant. One interpretation of the data is that the two states report alternate protonation states for H~173~. However, attempts to demonstrate a pH-dependent shift from one state to the other by adjusting the pH of the protein solution proved unsuccessful -- perhaps due to insufficient solvent exposure of this region of the heme coordination motif. Alternatively, the two states might reflect different conformational states of the heme as heme distortions can be associated with stronger axial ligand-heme bonding and changes in electronic structure of the iron center ([@bib49]; [@bib47]).

Heme coordination strategies of Sfh5 and hemophores of bacterial pathogens {#s3-4}
--------------------------------------------------------------------------

Hemophores are proteins secreted by bacterial pathogens that function in Fe-acquisition ([@bib46]; [@bib61]). These do so by scavenging heme from the host and, upon receptor-mediated retrieval of the hemophore/heme complex to the bacterial cell surface, releasing that micronutrient to the pathogen. HasA of *Serratia marcescens* and IsDX1 of *Bacillus anthracis* represent prototypical bacterial hemophores ([@bib69]; [@bib62]; [@bib37]; [@bib52]). While Sfh5 shares no sequence or structural homology to HasA or IsDX1, and Sfh5 is not secreted from the cell, the yeast protein does share interesting parallels in its heme coordination strategy with those hemophores. For example, HasA exhibits tyrosine (Y~75~) as one of two axial ligands, and an adjacent histidine (H~83~) H-bond acceptor stabilizes the tyrosinate ion and increases the affinity of heme binding ([@bib40]; [@bib13]; [@bib14]). Structural analyses of heme-bound HasA in complex with its bacterial surface receptor further suggest that transient protonation of the HasA H~83~ Nδ weakens the H-bond with Y~75~, reduces the affinity of HasA for heme, and facilitates heme release to the receptor ([@bib38]). Other heme-binding NEAT-domain proteins (e.g. IsdA and IsdH-N3 of *S. aureus* and IsdX1 of *B. anthracis*) employ Tyr-Tyr coordination motifs that operate via similar mechanisms ([@bib28]; [@bib67]; [@bib21]).

Sfh5 does not exhibit the properties of a heme donor {#s3-5}
----------------------------------------------------

Yeast cells synthesize heme in the mitochondria, but the mechanisms of intracellular heme transport and compartmentalization remain largely unresolved ([@bib54]; [@bib68]). In that regard, the interesting parallels between Sfh5 and heme-binding strategies of bacterial hemophores, when considered together with the activities of hemophores in binding and releasing heme on demand, suggested the possibility that Sfh5 functions in intracellular heme distribution. Two lines of evidence do not support this idea, however. First, consistent with the high affinity of Sfh5 for heme, the inability of an avid heme scavenger to withdraw heme from Sfh5 suggests Sfh5 is not designed to donate bound heme to some proteinaceous acceptor. One caveat associated with this interpretation is the formal possibility that Sfh5 donates heme to a highly privileged acceptor cannot yet be excluded. Second, Sfh5 exhibits only low-level PtdIns transfer activity in vitro and is ineffective in stimulating PtdIns 4-OH kinase activity in vivo. Yet, 'heme-less' Sfh5 mutants are resuscitated for both PtdIns-transfer activity in vitro and stimulation of PtdIns 4-OH kinase activity in vivo. These data report a fundamentally antagonistic relationship between heme- and PtdIns-binding where binding of the former is incompatible with exchange of the latter. We speculate that heme-binding locks Sfh5 into what is a substantially 'closed' conformer and that this represents the functional Sfh5 configuration. That holo-Sfh5 crystallizes as a 'closed' conformer is consistent with this view.

The enigmatic physiological function of the Sfh5 hemoprotein {#s3-6}
------------------------------------------------------------

Sfh5 does not play a major role in yeast heme biology under laboratory conditions -- at least not one accompanied by a recognizable phenotype. Yet, this hemoprotein is clearly conserved across the fungal kingdom. What then is the significance of the conserved heme-binding ability of Sfh5? One possibility is that heme represents a structural cofactor required for Sfh5 folding, and that Sfh5 activity does not otherwise leverage iron redox chemistry towards some biological function. The deeply sequestered heme pose in the internal Sfh5 cavity, its non-exchangeability, the fact that purified recombinant Sfh5 is very defective in PtdIns-transfer activity even though only some 1/3 of the molecules are heme-bound, and that Sfh5 is destabilized by removal of bound heme, are all consistent with such a scenario.

Two lines of evidence counter this idea, however. First, as described above, Sfh5 mutants unable to bind heme are well-folded proteins that exhibit robust PtdIns-exchange activity in vitro and are effective in stimulating PtdIns 4-OH kinase activities in vivo. Thus, these mutants are competent to undergo the significant conformational transitions required for PITP activity. Perhaps the corresponding amino acid substitutions exert the dual effects of rendering Sfh5 not only defective in heme-binding, but also sterically permissive for PtdIns-binding. This possibility is strongly supported by our demonstration that wild-type Sfh5 expressed in yeast cells devoid of heme remains incompetent for PITP activity in stimulating PtdIns 4-OH kinase activities in vivo. An innate steric incompetence of Sfh5 for PtdIns-binding provides yet another indication the protein is not designed to function as a PITP.

Second, chemogenomic analyses identify a specific 'heme-requiring' signature for Sfh5-deficient yeast challenged with the organic oxidant oltipraz -- an organosulfur compound that is not only used to treat schistosomiasis, but also exerts anti-cancer effects by inducing phase II carcinogen detoxification systems ([@bib64]; [@bib1]). Those data argue that heme binding by Sfh5 is physiologically relevant, but only when yeast are exposed to specific oxidative stressors. In that regard, the human pathogen *Cryptococcus neoformans* offers potential insight. This fungus causes lung infections that frequently progress to cryptococcal encephalomeningitis in immune-suppressed individuals and represents a leading cause of death in AIDS patients ([@bib15]). *C. neoformans* expresses three Sec14-like proteins -- a restricted cohort as fungi typically express at least five. Two of the *C. neoformans* Sec14-like proteins are orthologs of the canonical PtdIns/PtdCho-exchange PITP Sec14, and one is an Sfh5 ortholog ([@bib16]). Perhaps Sfh5 hemoproteins participate in stress responses to organic oxidants encountered by commensal and pathogenic fungi in host contexts, and by non-pathogenic yeast such as *Saccharomyces* in the wild.

Versatility of the Sec14-fold {#s3-7}
-----------------------------

Whereas the biological activity of Sfh5 remains enigmatic, what these collective results powerfully highlight is how evolution uses the Sec14-fold as a versatile scaffold for accommodating the binding of a wide variety of ligands. Our discovery of a novel class of Sec14-like hemoproteins now extends the diversity of ligand binding by members of the Sec14 PITP-like superfamily to molecules that are not lipids. That Sfh5 and its fungal orthologs exhibit an unusual heme coordination mechanism that includes a planar porphyrin, a redox-active iron, and co-axial Tyr and His residues packaged as an integrated electronic system, emphasizes the high complexity of ligand coordination possible with the Sec14-fold. Moreover, that this unique electronic system offers an available axial binding site suggests Sfh5 has a capacity to bind as yet unidentified substrate(s) and to execute new heme-based redox chemistry. It is an exciting proposition that the Sfh5-fold might ultimately prove amenable to the rational engineering of new redox nanoreactors designed for targeted modification of interesting organic molecules.

Materials and methods {#s4}
=====================

Yeast strains, plasmids, and media {#s4-1}
----------------------------------

The yeast strains used in this study were CTY182 (*MATa ura3-52 lys2-801 Δhis3-200*), CTY1-1A (*MATa ura3-52 lys2-801 Δhis3-200 sec14-1^ts^*), CTY558 (*MATα ade2 ade3 leu2 Δhis3-200 ura3-52 sec14Δ1::HIS3/pCTY11*) ([@bib7]; [@bib17]). Yeast strains constructed in this study included: YDK100 (CTY182 *sfh5Δ::KanmX4)*, VBY64 (CTY182 *sfh5Δ::KanmX4* ^His6^*SFH5::HIS3*), YDK112 (CTY182 *P~PMA1~::SFH5KanMX4-PMA1),* YDK113 (*MATa ura3-52 lys2-801 Δhis3-200 hem1*Δ::NatMX6) and YDK 114 (*MATa ura3-52 lys2-801 Δhis3-200 sec14-1^ts^ hem1Δ::NatMX6*). The *hem1Δ(6D)* mutant was a gift from Caroline Philpott (NIH). Structural genes encoding Sfh5 homologs were PCR-amplified from *S. cerevisiae*, *C. albicans* and *C. glabrata* genomic DNA and subcloned into pET28b+ vectors as *Nco*I and *Sac*I restriction fragments such that an 8 × histidine tag was incorporated at the N' terminus of each open reading frame. The Q5 site-directed mutagenesis kit was used in all site-directed mutagenesis experiments (New England Biolabs). The *HRG-1* coding region was amplified from cDNA prepared from *C. elegans* mRNA and subcloned into a modified pYES-DEST52 vector as a SacII/SphI fragment thereby placing *HRG-1* expression under *GAL1* promoter control. As control, *SFH5* from *S. cerevisiae* was similarly subcloned in parallel. The identities of all constructions were confirmed by DNA sequencing (Eton). Genetic methods and media used were previously described ([@bib34]; [@bib35]).

Protein expression and purification {#s4-2}
-----------------------------------

Sec14p was purified as described ([@bib58]). For Sfh5p, a pET28b(+) vector harboring 6 × His -Sfh5 was transformed into *E. coli* BL21 (DE3) cells and grown in Luria broth (LB) at 37°C. Upon the culture reaching OD~600~ = 0.5, protein expression was induced with isopropyl β-D-1-thiogalactopyranoside (80 µM final concentration), and the culture was incubated overnight at 16°C with shaking. Cells were harvested by centrifugation at 4°C, cell pellets were resuspended in buffer A (300 mM NaCl and 25 mM Na~2~HPO~4~, pH 7.0) with 2 mM PMSF and passed twice through a French Press at 10,000 psi. The crude lysate was clarified by centrifugation at 2800 g and then at 27,000 g. The clarified fraction was incubated with Co-NTA resin (TALON, Clontech) in the presence of 10 mM imidazole followed by wash with buffer A plus 20 mM imidazole. Sfh5 was eluted using a four-step gradient of buffer A supplemented with 50 mM, 100 mM, 200 mM and 400 mM imidazole. Fractions enriched in Sfh5 were reddish brown, and protein purity was monitored by SDS-PAGE. Peak fractions were pooled and subjected to three rounds of dialysis against buffer A, followed by size-exclusion chromatography on Sephadex 200 column (GE Healthcare). Sfh5 was stored at −80°C.

For isotopic labeling of Sfh5 with ^57^Fe-labeled heme, *E. coli* BL21(DE3) cells were transformed with the His~6~-Sfh5-pET28b(+) plasmid and a pre-inoculum was grown overnight in LB medium at 37°C. Cells were washed twice in modified M9 minimal medium (42 mM Na~2~HPO~4~, 22 mM KH~2~PO~4~, 8.5 mM NaCl, 18.5 mM NH~4~Cl, 2 mM MgSO~4~, 0.1 mM CaCl~2~ with 20 mM glucose) and grown in the same medium supplemented with 40 µM ^57^FeCl~3~ at 37°C until the culture reached an OD~600~ = 0.5. Sfh5 expression was induced with IPTG (final concentration 100 μM), and cells were incubated for 36 hr at 16°C with shaking. Cells were harvested and Sfh5 purified as described above. A 6 × His tagged version of Sfh5 was expressed in yeast under the control of the constitutive *PMA*1 promoter. Yeast cells were lysed by three rounds of passage through an LM20 microfluidizer (Siemens) at 30,000 psi. Sfh5 purification followed essentially the same procedure as that described for recombinant protein purification from *E. coli.*

Analysis of Sfh5-bound metal {#s4-3}
----------------------------

The metal contents of Sfh5 proteins were determined by ICP-MS. Proteins were digested overnight at 80°C in the presence of trace-metal grade nitric acid. Precipitated material was removed by centrifugation and the supernatant collected for analysis. Perkin Elmer Elan DRC II ICP-MS machine was used in collision cell mode (He, 4.5 mL/min) with a skimmer to minimize polyatomic inferences. A standard Micromist nebulizer (Glass Expansion, Australia) was used to introduce the sample. The dwell time for ^56^Fe analysis was 100 ms.

Mass spectrometry {#s4-4}
-----------------

Proteins were desalted with a C4 ZipTip (MilliporeSigma) and so prepared to achieve concentrations that ranged from 2 to 10 mg/ml. For matrix-assisted laser desorption ionization time of flight (MALDI TOF) mass spectrometry, a matrix solution composed of 10 mg/ml α-cyano-4-hydroxycinnamic acid (CHCA) in 50% acetonitrile and 0.1% trifluoroacetic acid (v/v) was made. One µL of the CHCA matrix was mixed with 1 µL of protein and allowed to dry at 30°C for 15 min. Approximately 1000 laser shots were collected for each sample on a Bruker Ultraflextreme MALDI TOF/TOF mass spectrometer with positive ion setting in the reflector mode. Hemin chloride (Sigma) was used as standard.

Sfh5 crystallization {#s4-5}
--------------------

Diffraction quality crystals were grown under conditions where 300 nL of a 10 mg/ml Sfh5 preparation was mixed with an equal volume of 0.1 M potassium thiocyanate, 0.1 M sodium citrate (pH 4.2) and 15.5--26% PEG 4000. Prior to data collection, crystals were cryoprotected with 20% (v/v) ethylene glycol, and flash-frozen in liquid nitrogen for data collection.

Model building and refinement {#s4-6}
-----------------------------

Data collection was performed on the 23-ID beamline of Advance Photo Source (APS) at Argonne National Laboratory, Chicago, IL, USA, with three different crystals at 8 keV (1.5498 Å). Data were indexed, integrated, merged and scaled with anomalous flags using *HKL2000* ([@bib50]). *Xtriage* predicted the anomalous signal for iron from the merged dataset to extend to 3.6 Å. For initial phasing, the resolution was set at 3.2 Å. The Sfh5 structure was solved using Phenix Autosol Wizard by single wavelength anomalous diffraction method using iron anomalous signal from three heavy atom positions in the asymmetric unit ([@bib4]). The data were submitted to Autobuild and an initial model was built. For subsequent refinement and model building, we chose a minimal complete subset of data with the best scaling statistics and resolution cut at 2.9 Å based on the intensity and CC1/2 analyses (data statistics for both phasing and refinement sets are given in [Table 1](#table1){ref-type="table"}). A well-defined electron density consistent with heme *b* was identified which correlated with the heavy atom positions. The coordinates and geometry definition files for the heme ligands were generated with Phenix Elbow ([@bib45]) without any artificial restraints. The initial model was improved by manual rebuilding in COOT ([@bib22]), and the final model was obtained after iterative cycles of model building and Phenix refinement. Statistics related to data collection and refinement are given in [Table 1](#table1){ref-type="table"}. The final structure was validated, and the atomic coordinates and structure factors for the structure were deposited in the Protein Data Bank with the accession code 6W32.

Protein preparation for in silico analysis {#s4-7}
------------------------------------------

Protein models were prepared using the *Protein Preparation Wizard* panel in the Schrödinger suite (2018--1, Schrodinger, LLC, Mew York, NY, 2018). The Sfh5 structure was optimized with the OPLS_2005 forcefield in the Schrödinger suite to relieve all atom and bond strains found after adding all missing side chains and/or atoms. The Sfh5::PtdIns model was generated by structural overlay of Sfh1::PtdIns complex (PDB ID 3B7N; [@bib58]) on Sfh5 monomer. The heme group of Sfh5 was replaced by PtdIns, which was extracted from Sfh1. The Sfh5::PtdIns complex was energy minimized to relieve Sfh5 and PtdIns atoms of any van der Waal steric clashes and complex was optimized for electrostatic interactions. Molecular graphics and analyses were performed with UCSF Chimera and Schrödinger's Maestro program.

Hydrodynamic analyses {#s4-8}
---------------------

Equilibrium sedimentation of Sfh5 in 50 mM NaPO~4~, 300 mM NaCl (pH 7.0) was performed at 4°C on an Optima XL-A Analytical Ultracentrifuge (Beckman Coulter). Equilibrium radial distributions at 10,000 and 15,000 RPM of Sfh5 at concentrations of 10, 5 and 2.5 µM were recorded via UV absorbance at 280 nm. All data (two speeds, three concentrations) were fit globally to a single ideal species with floating molecular weight using nonlinear least squares using the HETEROANALYSIS software 1. Protein partial specific volume and buffer density were calculated with SEDNTERP 2.

UV-visible absorbance spectroscopy {#s4-9}
----------------------------------

Absorbance measurements were performed on a Cary Varian Bio 100 UV-vis spectrophotometer (Varian) at room temperature. The slit width for all measurements was 1 nm and spectra were collected at a rate of 500 nm per minute. Quartz cuvettes were used for all measurements.

Pyridine hemochromagen assay {#s4-10}
----------------------------

Heme was identified and quantified using a pyridine hemochromagen assay performed as described ([@bib9]). Briefly, 0.5 ml of protein solution of fixed concentration (30 μM) was oxidized by adding a 0.5 ml cocktail of 0.2 M sodium hydroxide, 40% (v/v) pyridine and 500 µM potassium ferricyanide, and a UV-vis absorption spectrum was collected. Following addition of 1 mg of sodium dithionite, a second spectrum was collected. Appearance of α and β bands at 557 and 525 nm respectively, in the Fe^2+^ state were taken as evidence of heme *b*. Using known extinction coefficients for pyridine hemochromagens, heme contents were quantified for each sample.

EPR spectroscopy {#s4-11}
----------------

Purified proteins were collected in Wilmad Suprasil EPR tubes and gently frozen in liquid N~2~ and stored until data acquisition. EPR spectra involved a 5000G sweep on an X-band EMX spectrometer (Bruker Biospin Corp) with a bimodal resonator and cryostat for maintaining a low temperature of 4K. Average microwave frequency, 9.38 GHz; microwave power, 0.2 W; modulation amplitude, 10 G; average time = 300 s. All spectra were normalized and plotted using SpinCount software (<http://www.chem.cmu.edu/groups/heindrich>). A 1 mM solution of CuSO~4~-EDTA was used as a standard.

Mössbauer spectroscopy {#s4-12}
----------------------

Low-field (0.5 T), low-temperature (5K) Mössbauer spectra were collected using a model MS4 WRC spectrometer (See Co. Edina, MN). Variable field (0--6 T), 4.2 K spectra were collected using a model LHe6T spectrometer. Both instruments were calibrated using an α-Fe foil at room temperature. Approximately 800 µl of recombinant proteins (concentration = 1.5 mM) were collected in a Mössbauer cup, frozen over liquid nitrogen and stored at −80°C until use. Spectra were simulated using WMOSS (<http://www.wmoss.org>).

Peroxidase assays {#s4-13}
-----------------

Peroxidase assays were performed as described by [@bib44]. Briefly, the appropriate protein samples were incubated with pyrogallol and its conversion to purpugallin was monitored spectrophotometrically at 420 nM wavelength as a function of time. One unit of peroxidase activity was defined as formation of 1 mg of purpurogallin in 20 s from the substrate at pH 7.0 at room temperature. Activities were normalized to protein heme content as determined by ICP-MS and pyridine hemochromagen assay.

PtdIns transfer assays {#s4-14}
----------------------

The assays were performed using rat liver microsomes as \[^3^H\]-PtdIns donor and PtdCho liposomes as acceptor as previously described ([@bib58]). All incubations were for 30 min at 37°C.

In vitro heme transfer {#s4-15}
----------------------

Apo-myoglobin was prepared by methy-ethyl ketone extraction of heme from equine skeletal myoglobin as previously described ([@bib19]). Heme-free apo-myoglobin (10 µM) was incubated with hemin (30 µM) and Sfh5 (35 µM) as indicated for different time periods and resolved on non-reducing SDS-PAGE gels run in duplicate. One gel was stained with Coomassie Blue and other was transferred onto a nitrocellulose membrane and probed for peroxidase activity using SuperSignal West Femto Maximum Sensitivity Substrate reagent (Thermo Fisher). Heme transfer from Sfh5 donor to apo-myoglobin acceptor was monitored by peroxidase activity in the myoglobin bands ([@bib23]).

Solvent accessible surface area calculations {#s4-16}
--------------------------------------------

SASA of Sfh5 with and without bound heme were calculated using the Schrodinger binding SASA script. This routine calculates solvent accessible surface area of ligand and receptor before and after receptor-ligand binding. A default cutoff of a 5 Å radius around the heme ring system was used to compute SASA of the heme binding site before and after heme binding to Sfh5.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

This manuscript shows how evolution has reshaped a binding pocket that normally harbours phospholipid, into a heme-binding pocket. It will be very interesting to investigate the physiological role of heme binding in the future; the crystal structure and thorough biochemical characterization of the Sfh5 protein show an unambiguous and unexpected twist in the evolution of lipid binding proteins that is of high interest to a wide readership.

**Decision letter after peer review:**

Thank you for submitting your article \"A Sec14-like phosphatidylinositol transfer protein paralog defines a novel class of heme-binding proteins\" for consideration by *eLife*. Your article has been reviewed by four peer reviewers, including Benoit Kornmann as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by a Reviewing Editor and Cynthia Wolberger as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Amit R Reddi (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, when editors judge that a submitted work as a whole belongs in *eLife* but that some conclusions require a modest amount of additional new data, as they do with your paper, we are asking that the manuscript be revised to either limit claims to those supported by data in hand, or to explicitly state that the relevant conclusions require additional supporting data.

Our expectation is that the authors will eventually carry out the additional experiments and report on how they affect the relevant conclusions either in a preprint on bioRxiv or medRxiv, or if appropriate, as a Research Advance in *eLife*, either of which would be linked to the original paper.

Summary:

This manuscript reports the unusual reconfiguration of a phospholipid binding pocket into a heme binding pocket. Structural analysis of the PhosphatidylInositol Transfer Protein (PITP) Sfh5 shows that the protein binds heme with an unusual electronic arrangement in anpocket that is normally occupied by PI. Analysis of the residues involved in binding and of the affinity to heme indicate that heme is redox active, could adsorb another ligand on one side of the iron atom, and is bound to the protein almost irreversibly.

Examining published pharmacogenomics screens unveils a link between Sfh5 and a potential redox response.

Notwithstanding some problems in crystallography interpretation (see below), all four reviewers found that the study was carefully executed, and that the repurposing of a lipid-binding pocket to a heme-binding pocket was surprising and interesting. They felt however that the biological function of heme-binding by Sfh5 was insufficiently investigated. In particular, reviewers 1, 2 and 3 felt that it was at this stage premature to conclude that Sfh5 had lost its ability to bind PI or that heme-binding was not regulating PI binding. A role of Sfh5 as a PITP should therefore not be discounted at this point given how easy it is to resuscitate this function, and given that the concentrations of heme and PI might allow a fair fraction of Sfh5 to be PI-bound in vivo.

Essential revisions:

Reviewer 2 proposes an experiment that could shed light on a possible role of Sfh5 as heme-regulated PITP. Heme levels can be titrated up and down in cells. To do this, heme is first made dispensable by providing ergosterol in the medium (the essential function of heme is in ergosterol biosynthesis). In this condition the aminolevulinate synthase HEM1 can be deleted. Heme levels can then be tuned by adding back given amounts of aminolevulinic acid (which is imported into cells).

Since you show that a heme-binding deficient Sfh5 mutant recovers its PITP activity (in Sec14 delete cells), it is to be expected that wildtype Sfh5 will function as PITP in heme-less cells. Here, by increasing the amount of aminolevulinate (and thus of intracellular heme), Sfh5 should gradually lose its PITP activity. Such an experiment should be quite straightforward and could shed light on the levels of heme necessary to inhibit the PITP function of Sfh5.

Moreover, reviewer 4 found substantial problems with the validation of the structure based on the density map (see their point 4). The map has also been checked by an independent expert, who saw nothing wrong with the number of molecules per unit cell, but agreed that there are a lot of issues with the structure that need to be fixed.

\- The validation report also flagged issues with the heme geometry that should be fixed.

\- The large number of clashes and protein geometry issues come from poorly traced chains in the C-terminal residues of chains A and C, and in all three copies in the vicinity of residues 40-45. One can see very clearly from the density that the fit is incorrect and violates various geometric constraints. These are all fixable and probably don\'t affect the interpretation.

Reviewer \#1:

This manuscript describes the recombinant expression, purification and structural analysis of Sfh5, a Sec Fourteen Homolog, and the surprising discovery that, unlike Sec14 and other related proteins, Sfh5 doesn\'t appear to bind the phospholipid phosphatidylinositol (PI), but instead binds heme tightly and through an unusual network of bonds. The physiological implication of this binding is not yet understood, but experimental indications allow the authors to speculate on possible roles. First, because the iron center of heme is pentavalent, and that a cavity exists where the sixth bond would be, suggesting that a secondary substrate could bind here (like O2 in hemoglobin). Second, the analysis of a chenogenomics screen shows that Sfh5 mutant cells are sensitive to heme-depleting drugs.

This is a very intriguing story that certainly asks more questions than it answers. It is carefully executed and exhaustive. It will certainly lay the ground for further research.

Essential revisions:

\- The authors speculate that Sfh5 doesn\'t bind PI in a physiological setting and is unlikely to exchange heme for PI, given the difference in affinity to both metabolites. This is somewhat contradictiry with the fact that PI binding can apparently be rescued by abrogating heme binding, indicating that PI binding has been kept throughout evolution. The authors mention a \"barcode\" of aminoacids necessary for PI binding, which all have been kept in Sfh5. Moreover, mutating one amino acid of this barcode allows a heme-binding-deficient mutant to regain heme binding to some extent, suggesting that it is PI binding that prevents heme binding in the heme-defective mutant. So what are the amino-acids of this barcode? Are they conserved, and if so, why?

If the \"resuscitable\" PI-binding ability of Sfh5 is conserved, then it probably means that PI-binding is an important property of the protein.

Also, the concentrations of heme and PI might be very different wherever Sfh5 is located, which might compensate for the different inherent affinities. Finally, the authors rightly acknowledge that \"the formal possibility that Sfh5 donates heme to a highly privileged, and as-yet-unidentified, acceptor cannot be excluded\", they do not acknowledge the possibility that Sfh5 binding to a third party factor (not necessarily a heme-acceptor) might decrease its affinity for heme in vivo. These points suggest that it could be premature to dismiss the possibility that heme/PI exchange might actually happen in vivo. This possibility does not alter the interest of the present study and can be addressed in further studies.

\- This manuscript talks to scientists with very different sets of expertise. The thorough characterization of the biophysical properties of Sfh5 could in general do with more complete explanations of the various methods in use. For instance:

Soret spectra are calibrated against mock-expressing bacterial lysate. This information could go in the text or figure legend rather than the Materials and methods section.

\"The isostructural A10/T4 gating helices of Sfh1 and Sfh5 were positioned similarly across the opening to the internal cavity\". The corresponding figure could benefit from better description (no labels on the helices).

\"tyrosine coordination was consistent with the results of safranin T dye-reduction assays which estimated an unusually low thermodynamic reduction potential for Sfh5 heme (-330 ± 3 mV vs. NHE).\" This could require better explanations (e.g. NHE is not described anywhere).

Reviewer \#2:

The authors describe an unusual but very interesting member of a class of Sec14-like phosphatidylinositol transfer proteins (PITP), Sfh5. They find that Sfh5 is a novel heme binding protein and, in fact, does not function in activities typically associated with PITPs. Most interestingly, they find that variants of Sfh5 that cannot bind heme restores PITP activity. The major focus of the study is on the biophysical characterization of Sfh5 and its interactions with heme. The work is technically sound, beautifully integrating rigorous structural, spectroscopic, and biochemical characterization of Sfh5, and the manuscript is very well written. However, the studies may not have broad appeal due to the lack of cell biological data demonstrating the physiological significance of heme-Sfh5 interactions.

Essential revisions:

1\) The paper is technically sound but may be of limited impact due to the lack of data establishing a physiological function for heme binding. In this sense, significant efforts must be made to establish a role for heme binding. As it currently stands, the work may be more appropriate for a specialized audience of biochemists.

2\) The authors should comment on how the PITP activity of the heme-binding mutants of Sfh5 compare to other Sec14-like PITPs? These mutants may have more PITP activity than WT Sfh5, but is the activity comparable to other more typical Sec14-type PITPs?

The following suggestions are outside the scope of the current study as presented. I hope the comments may prove useful to the authors as they continue their studies on this interesting protein.

3\) Do the authors think heme plays a regulatory role in Sfh5 phosphatidylinositol transfer activity? For instance, it is mentioned that only 1/3 of the protein is heme loaded. Does increasing heme synthesis decrease PITP activity in vivo? If the authors fed WT cells porphobilinogen (PBG), which would increase heme levels, or titrate aminolevulinic acid (ALA) in *hem1∆* cells, is there a dose dependent decrease in Sfh5-related PITP activity in vivo? An experiment such as this demonstrating in vivo regulation of PITP activity by heme would greatly elevate the significance/impact of the current work.

Note, in *Saccharomyces cerevisiae*, ALA synthase is not the rate-limiting enzyme for heme synthesis, as it is in other eukaryotes. Thus, to drive heme synthesis in WT cells, one must use PBG.

4\) The authors make the intriguing comment that there may be a privileged acceptor that Sfh5 may donate heme to. Related to this point, I am wondering if heme reduction could induce its dissociation? I understand that the myoglobin transfer experiments were done with ferric heme. Could heme dissociate and transfer to myoglobin if it were reduced with dithionite?

Sfh1 in some sense reminds me of yeast Dap1, a homolog of mammalian PGRMC1 and PGRMC2. Dap1 is a low potential hemoprotein (\~-300 mV) that binds heme with a tyrosine ligand. It was thought that Dap1 might be a heme chaperone for ER localized Cytochrome P450s, although this is controversial. *dap1∆* exhibits fluconazole and MMS sensitivity, in part due to defects in ergosterol biosynthesis, which requires a P450 enzyme. The authors may want to consider looking at fluconazole sensitivity, or defects in the ergosterol biosynthetic pathway. There was recently a paper in Nature describing role of PGRMCs in nuclear heme trafficking in adipocytes.

Reviewer \#3:

This study demonstrates that a member of the large Sec14-like phosphatidylinositol transfer protein (PITP) family, Sfh5, binds heme. This is the first member of this family found to bind heme. The structure of Sfh5 bound to heme is presented and the interactions of the protein with heme and Fe chemistry of the bound heme are carefully examined. While it is fascinating (and surprising) that a PITP binds heme, the study does not shed much light on the functional significance of heme binding by Sfh5. It argues that the protein is unlikely to be a phosphatidylinositol-heme exchanger and shows that Sfh5 does not efficiently deliver heme to the heme-acceptor apo-myoglobin, consistent with the idea that Sfh5 does not supply heme to other proteins. Instead, it suggests that heme bound Sfh5 somehow participates in a cellular response to oxidants but offers no insight into how this might occur. Even without this, I think the finding that PITPs can bind heme is an important discovery and this study could be appropriate for *eLife*. I have two major concerns.

1\) The affinity of Sfh5 for heme should be examined in more detail. This study suggests bound heme is not a readily exchangeable, but this is difficult to square with the statement in the discussion that only 1/3 of Sfh5s are heme-bound. The fraction of endogenous Sfh5 bound to heme should be determined and shown. It is important that these measurements be made with protein lacking a His-tag since this tag bind heme. If it is correct that bound heme is not readily exchangeable but only a fraction of the protein is heme-bound, some effort should be made to explain this. Is the on rate very slow?

2\) The study demonstrates that heme bound by Sfh5 is accessible to small ligands like CN^-^, indicating that the heme is redox active, but does not explain how changes in the redox state of bound heme could be physiologically relevant. How could these changes be sensed by other proteins? Or how do the authors think bound heme could significantly contribute to cytoplasmic redox chemistry?

Reviewer \#4:

Khan et al, report a novel heme-binding function for a member (Sfh5) of a class of yeast proteins (PITPs) that normally transfer lipids. They report a crystal structure of heme-bound Sfh5 and thoroughly describe the biophysical and structural properties of the heme-bound complex using absorption, EPR, and Mössbauer spectroscopies. Data presented indicate that wild-type Sfh5 neither exchanges phosphatidylinositol nor heme. Experiments indicate that yeast deficient of Sfh5 show no significant functional phenotype. However, mining of a \"comprehensive HIPHOP chemogenomic study\" lead the authors to propose that Sfh5 may be involved in controlling \"some aspect of redox control, and/or regulation of heme homeostasis, under stress conditions induced by exposure to organic oxidants\" -- a hypothesis that was not experimentally explored in this study.

The strengths of this manuscript are the novelty that a Sec14-like protein can bind heme, and the thorough characterization of the structural and biophysical basis for heme binding. The significance of the \"unusual heme-binding arrangement\" described in detail in this study is not readily apparent. Furthermore, no biological function was detailed in this study that is supported by data. A more robust functional role for Sfh5\'s heme-binding properties would strengthen this story.

Essential revisions:

1\) Introduction: The authors provide a lot of information about the lipid-dependent activities of the PITPs, given that their protein of interest (Sfh5) does not bind lipid and does not appear to function in the manner consistent with PITP function. Since it appears that the function of Sfh5 is unknown (which is interesting), perhaps this should be stated up front along with any information known about its biology in yeast and other eukaryotic homologs-then more briefly mention the functions of related Sec14-like PITPs and lipid-dependent activities as a possible function (i.e., present a hypothesis). The first paragraph of the Results section could be moved up to the Introduction.

2\) Most of the work to show that Sfh5 binds heme was performed using protein expressed in bacteria, which produced heme-bound Sfh5 that copurifed during purification steps. One experiment is shown to link heme binding to Sfh5 in yeast cells (Figure 1C, lower right panel) but the data signal-to-noise is very low for the yeast protein compared to the bacterial protein and no control is provided to show the heme interaction in the yeast pull-down experiment is specific. Can growth conditions for bacterial or yeast grown be discovered that allow purification of heme-free Sfh5-or biochemical stripping/unfolding/repurification of heme-free protein-which can then be used in heme binding analysis via absorbance or ITC measurements and phosphatidylinositol binding assays?

3\) There is no functional evidence presented to prove that Sfh5, which is expressed at low levels and shows no deletion functional phenotype, or its unique heme-binding properties are important in yeast or any other organism. Is it possible Sfh5 could be vestigial in yeast? Do related proteins from other organisms (i.e., those that evolutionarily precede yeast) express Sfh5 with higher expression and more robust heme-dependent functional activities. If Figure 8---figure supplement 2 provides the only insight into the potential functional relevance of Sfh5, the authors should consider moving it to a main figure.

4\) Crystallography: The authors show that Sfh5 is a homodimer using AUC; however, no dimerization was observed in the crystal structure. An issue related to this that should be addressed: when the sfh5_map_coeffs.mtz file provided by the authors is analyzed in CCP4, the Matthews_coef analysis (estimate of the number of asymmetric units in the unit cell) indicates there should be 4 molecules (e.g., two dimers?) in one unit cell with a solvent content \~52.2%. However, the authors solved the structure with 3 molecules in one unit cell. Other issues that should be addressed pertaining to the structure refinement include (1) the Ramachandran outliers in the validation report is 0.5%, which is inconsistent with 0% reported by the authors in the Table 1; (2) the percent of residues with favored Ramachandran is 86%, which can likely be improved; and (3) the R-factor gap (R~work~/R~free~) is large. Finally, the number of atoms in the protein (129) and ligand (5) reported by the authors in Table 1 needs to be corrected.

5\) Figure 7: The authors prepared apo-myoglobin by methy-ethyl ketone extraction of heme from equine skeletal myoglobin for use in heme-transfer assays to determine if Sfh5 can exchange heme via detection of heme transfer to apo-myoglobin. However, they do not show a critical positive control showing that free heme can bind to their prepared apo-myoglobin to demonstrate the protein is functionally capable of binding heme.

10.7554/eLife.57081.sa2

Author response

> Essential revisions:
>
> Reviewer 2 proposes an experiment that could shed light on a possible role of Sfh5 as heme-regulated PITP. Heme levels can be titrated up and down in cells. To do this, heme is first made dispensable by providing ergosterol in the medium (the essential function of heme is in ergosterol biosynthesis). In this conditions the aminolevulinate synthase HEM1 can be deleted. Heme levels can then be tuned by adding back given amounts of aminolevulinic acid (which is imported into cells).
>
> Since you show that a heme-binding deficient Sfh5 mutant recovers its PITP activity (in sec14 delete cells), it is to be expected that wildtype Sfh5 will function as PITP in heme-less cells. Here, by increasing the amount of aminolevulinate (and thus of intracellular heme), Sfh5 should gradually lose its PITP activity. Such an experiment should be quite straightforward and could shed light on the levels of heme necessary to inhibit the PITP function of Sfh5.

Please see the response to reviewer 2, point 3.

> Moreover, reviewer 4 found substantial problems with the validation of the structure based on the density map (see their point 4). The map has also been checked by an independent expert, who saw nothing wrong with the number of molecules per unit cell, but agreed that there are a lot of issues with the structure that need to be fixed.

The geometry restraints file used for the heme was based on ideal geometry, and refinement was run in Phenix with default data/geometric weights. The refined heme fits the density very well but has slight deviation of the bond lengths RMSZ = 2.02-2.11 for ideal lengths (greatest deviation is 0.16 Å) and greatest bond angle deviation from ideal is by 5.99°. It is not uncommon for heme to have slightly distorted geometries when bound to proteins. (For examples in PNAS May 6, 2014 111 (18) 6570-6575; JBC June 18, 2004279, 26489-26499.)

> -The validation report also flagged issues with the heme geometry that should be fixed.
>
> -The large number of clashes and protein geometry issues come from poorly traced chains in the C-terminal residues of chains A and C, and in all three copies in the vicinity of residues 40-45. One can see very clearly from the density that the fit is incorrect and violates various geometric constraints. These are all fixable and probably don\'t affect the interpretation.

The editor is correct to point out that chains A andC have problems, and we should have explained this in the manuscript (and now we do). The two chains are highly disordered in the crystal lattice (except for core of the protein where the heme is bound). This was observed for several diffraction data sets including the SAD. However, chain B is very well ordered except for residues 40-45 and we used Chain B for our interpretations in the manuscript. Chain B has 100 % model fit to the data according to RSRZ validation score, no Ramachandran outliers, and only Tyr34 ring clashes with Leu205 and Leu33 side chains hydrogens. Majority of listed clashes are with hydrogens (added to the model by a program for validation), which cannot be accounted for at this resolution, and are not present in the deposited model. Also, majority of the clashes are in regions with poor density, and where there are sidechains that could exist in multiple conformations.

> Reviewer \#1:
>
> \[...\]
>
> Essential revisions:
>
> \- The authors speculate that Sfh5 doesn\'t bind PI in a physiological setting and is unlikely to exchange heme for PI, given the difference in affinity to both metabolites. This is somewhat contradictory with the fact that PI binding can apparently be rescued by abrogating heme binding, indicating that PI binding has been kept throughout evolution. The authors mention a \"barcode\" of aminoacids necessary for PI binding, which all have been kept in Sfh5. Moreover, mutating one amino acid of this barcode allows a heme-binding-deficient mutant to regain heme binding to some extent, suggesting that it is PI binding that prevents heme binding in the heme-defective mutant. So what are the amino-acids of this barcode? Are they conserved, and if so, why?
>
> If the \"resuscitable\" PI-binding ability of Sfh5 is conserved, then it probably means that PI-binding is an important property of the protein.
>
> Also, the concentrations of heme and PI might be very different wherever Sfh5 is located, which might compensate for the different inherent affinities. Finally, the authors rightly acknowledge that \"the formal possibility that Sfh5 donates heme to a highly privileged, and as-yet-unidentified, acceptor cannot be excluded\", they do not acknowledge the possibility that Sfh5 binding to a third party factor (not necessarily a heme-acceptor) might decrease its affinity for heme in vivo. These points suggest that it could be premature to dismiss the possibility that heme/PI exchange might actually happen in vivo. This possibility does not alter the interest of the present study and can be addressed in further studies.

The barcodes they are referring to here is the PtdIns binding residues that are conserved in Sec14 and in all Sec14-like proteins \-- including in all Sfh5 homologs. These are Y~68~ in Sfh5/R~65~ in Sec14, E~204~/E~207~, K~236~/K~239~, T~233~/T~236~, etc. These conserved residues are identified with a ▲ in Figure3---figure supplement 1.

Regarding the Y68 mutant that compromises the PtdIns-binding barcode, we really do not know how to interpret the fact that this specific mutation *restores* a small amount of heme binding to the Y175F mutant which is normally heme-less as it has lost the coordinating tyrosine. But, we felt we had to report the result because it was so unexpected. Perhaps H173 now coordinates the heme in this mutant (albeit very poorly). How and why this happens we have no good idea at the moment. We do not think there is a competition between PtdIns and heme binding, however. We hypothesized this to be the case initially but all data were most simply interpreted to the contrary. Evidence to that effect is covered in more detail in the response to reviewer 2 point 3.

> \- This manuscript talks to scientists with very different sets of expertise. The thorough characterization of the biophysical properties of Sfh5 could in general do with more complete explanations of the various methods in use. For instance:
>
> Soret spectra are calibrated against mock-expressing bacterial lysate. This information could go in the text or figure legend rather than the Material and methods section.

Revised as requested.

> \"The isostructural A10/T4 gating helices of Sfh1 and Sfh5 were positioned similarly across the opening to the internal cavity\". The corresponding figure could benefit from better description (no labels on the helices).

The figure is now clarified by labeling the iso-structural gating helices.

> \"tyrosine coordination was consistent with the results of safranin T dye-reduction assays which estimated an unusually low thermodynamic reduction potential for Sfh5 heme (-330 ± 3 mV vs. NHE).\" This could require better explanations (e.g. NHE is not described anywhere).

We now define NHE (normal hydrogen electrode).

> Reviewer \#2:
>
> \[...\]
>
> Essential revisions:
>
> 1\) The paper is technically sound but may be of limited impact due to the lack of data establishing a physiological function for heme binding. In this sense, significant efforts must be made to establish a role for heme binding. As it currently stands, the work may be more appropriate for a specialized audience of biochemists.

We concede the basic fact that, try as we might, we have yet to establish a physiological function for Sfh5 but the fact that it defines a novel clade of fungal hemoproteins is consistent with it having an important, although perhaps a boutique, function.

> 2\) The authors should comment on how the PITP activity of the heme-binding mutants of Sfh5 compare to other Sec14-like PITPs? These mutants may have more PITP activity than WT Sfh5, but is the activity comparable to other more typical Sec14-type PITPs?

The specific activity of the heme-binding Sfh5 mutants is comparable to those of Sec14 and other yeast Sfh PITPs (Sfh1 is not an active PITP):

Sfh5 / Sec14: 0.1

Sfh5^Y175F^ / Sec14: 0.7

Sfh5^Y175F^ / Sfh2: 0.7

Sfh5^Y175F^ / Sfh3: 1.0

Sfh5^Y175F^ / Sfh4: 0.8

The only one that is relevant to this is the Sec14 comparison and that value is now stated in the text.

> The following suggestions are outside the scope of the current study as presented. I hope the comments may prove useful to the authors as they continue their studies on this interesting protein.
>
> 3\) Do the authors think heme plays a regulatory role in Sfh5 phosphatidylinositol transfer activity? For instance, it is mentioned that only 1/3 of the protein is heme loaded. Does increasing heme synthesis decrease PITP activity in vivo? If the authors fed WT cells porphobilinogen (PBG), which would increase heme levels, or titrate aminolevulinic acid (ALA) in hem1∆ cells, is there a dose dependent decrease in Sfh5-related PITP activity in vivo? An experiment such as this demonstrating in vivo regulation of PITP activity by heme would greatly elevate the significance/impact of the current work.
>
> Note, in Saccharomyces cerevisiae, ALA synthase is not the rate-limiting enzyme for heme synthesis, as it is in other eukaryotes. Thus, to drive heme synthesis in WT cells, one must use PBG.

Why is only 30% of the protein occupied by heme? We suspect it is because *E. coli* does not make sufficient heme to occupy the amount of Sfh5 produced. We did test to see if supplementing the induction culture with α-ALA increased heme occupancy. It did not. We expound on this point in more detail in our response to reviewer 3 point 1 below.

Reviewer 2 suggests a clever and informative experiment and we are grateful for the input. We performed the version of this experiment outlined by the Editor in the Essential revisions for this paper. The experiment performed assessed whether Sfh5 over-expression in a heme-less *hem1∆* yeast strain cultured on ergosterol-containing medium could recapitulate phenotypic rescue of the *sec14ts* mutation as is seen for the heme-binding mutants, and whether this rescue could be abrogated by heme synthesis induced by ALA supplementation. We show these results in a revised Figure 7 -- specifically a new Figure 7C. Sfh5 over-expression failed to rescue *sec14ts* defects at 37°C in heme-less cells. These data indicate WT Sfh5 that is not heme-bound is nonetheless an inactive PITP whereas a mutant defective in heme-binding has PITP activity. We interpret the data to indicate the heme coordinating residues in WT Sfh5 are incompatible with PtdIns binding while substitutions that result in heme-binding deficiency have the dual effects of compromising heme coordination and being compatible with PtdIns binding.

> 4\) The authors make the intriguing comment that there may be a privileged acceptor that Sfh5 may donate heme to. Related to this point, I am wondering if heme reduction could induce its dissociation? I understand that the myoglobin transfer experiments were done with ferric heme. Could heme dissociate and transfer to myoglobin if it were reduced with dithionite?

We have performed this experiment using a more cumbersome Soret-based assay and find that dithionite reduction does not render Sfh-bound heme exchangeable in an apo-myoglobin loading assay. This result is now indicated in the text.

> Sfh1 in some sense reminds me of yeast Dap1, a homolog of mammalian PGRMC1 and PGRMC2. Dap1 is a low potential hemoprotein (\~-300 mV) that binds heme with a tyrosine ligand. It was thought that Dap1 might be a heme chaperone for ER localized Cytochrome P450s, although this is controversial. dap1∆ exhibits fluconazole and MMS sensitivity, in part due to defects in ergosterol biosynthesis, which requires a P450 enzyme. The authors may want to consider looking at fluconazole sensitivity, or defects in the ergosterol biosynthetic pathway. There was recently a paper in Nature describing role of PGRMCs in nuclear heme trafficking in adipocytes.

Thank you for the suggestion. The *sfh5∆* allele does not alter fluconazole sensitivity of yeast nor does it show any obvious genetic interactions with defects in the ergosterol biosynthetic pathway. But this general idea is one that merits attention.

> Reviewer \#3:
>
> \[...\]
>
> 1\) The affinity of Sfh5 for heme should be examined in more detail. This study suggests bound heme is not a readily exchangeable, but this is difficult to square with the statement in the discussion that only 1/3 of Sfh5s are heme-bound. The fraction of endogenous Sfh5 bound to heme should be determined and shown. It is important that these measurements be made with protein lacking a His-tag since this tag bind heme. If it is correct that bound heme is not readily exchangeable but only a fraction of the protein is heme-bound, some effort should be made to explain this. Is the on rate very slow?

We demonstrate that position of the His-tag in Sfh5 does not affect its heme-binding properties, and that a His-tagless version of Sfh5 retains:

1\) heme-binding activity, and

2\) the crystal structure unambiguously places the heme-binding pose in the internal hydrophobic pocket of Sfh5 far away from the His-tag.

Moreover, we find no evidence from extensive studies with other related His-tagged Sec14-like PITPs that the His-tag endows some artifactual heme-binding activity.

Why is only 30% of the protein occupied by heme? As addressed above for reviewer 2 point 3, we suspect it is because *E. coli* does not make sufficient heme to occupy the amount of Sfh5 produced. We did test to see if supplementing the induction culture with α-ALA increased heme occupancy. It did not for Sfh5 so it remains formally possible that the on-rate is slow. However, those results are also consistent with a model where heme is loaded co-translationally with a fast on-rate. It remains a formal possibility that, without sufficient available heme, a fraction of the protein subtly malfolds and cannot be loaded with heme once it goes off-pathway. We have tried several methods to strip purified Sfh5 of bound heme but the end result is always aggregation. We hope all will agree that the important questions relating to the mechanism of heme-loading, the kinetics of heme loading, etc are outside the scope of this work and could not be completed in a reasonable time frame.

> 2\) The study demonstrates that heme bound by Sfh5 is accessible to small ligands like CN-, indicating that the heme is redox active, but does not explain how changes in the redox state of bound heme could be physiologically relevant. How could these changes be sensed by other proteins? Or how do the authors think bound heme could significantly contribute to cytoplasmic redox chemistry?

The questions posed by the reviewer are important and rather broad ones. However, without a physiological context from which to investigate these questions, we do not know how we can address the questions posed. We can only speculate. Given the HIP-HOP data our current hypothesis is that Sfh5 could function to detoxify an organic oxidant(s). Hemoproteins that exhibit such activities typically show very high specificity towards, and high specific activity against, their privileged substrates. But these proteins exhibit very low activities towards other substrates. So, we would need to go fishing for substrate -- a daunting task with no clear prospects for success. We hope all will agree that the questions posed, while of critical importance, are simply not experimentally accessible at this time.

> Reviewer \#4:
>
> \[...\]
>
> Essential revisions:
>
> 1\) Introduction: The authors provide a lot of information about the lipid-dependent activities of the PITPs, given that their protein of interest (Sfh5) does not bind lipid and does not appear to function in the manner consistent with PITP function. Since it appears that the function of Sfh5 is unknown (which is interesting), perhaps this should be stated up front along with any information known about its biology in yeast and other eukaryotic homologs-then more briefly mention the functions of related Sec14-like PITPs and lipid-dependent activities as a possible function (i.e., present a hypothesis). The first paragraph of the Results section could be moved up to the Introduction.

Revised as requested.

> 2\) Most of the work to show that Sfh5 binds heme was performed using protein expressed in bacteria, which produced heme-bound Sfh5 that copurifed during purification steps. One experiment is shown to link heme binding to Sfh5 in yeast cells (Figure 1C, lower right panel) but the data signal-to-noise is very low for the yeast protein compared to the bacterial protein and no control is provided to show the heme interaction in the yeast pull-down experiment is specific. Can growth conditions for bacterial or yeast grown be discovered that allow purification of heme-free Sfh5-or biochemical stripping/unfolding/repurification of heme-free protein-which can then be used in heme binding analysis via absorbance or ITC measurements and phosphatidylinositol binding assays?

Sfh5 is expressed at very low levels in yeast cells and purifying it from yeast in any quantity is a challenge. The question was whether Sfh5 purified from yeast came bound to heme and it does. We trust all will agree the weight of the data identify Sfh5 as a bona fide hemoprotein. We have tried hard to produce heme-free Sfh5 by various methods exactly for the purposes suggested by the reviewer. Those efforts have met with no success. The protein from which heme is extracted simply aggregates in all cases and, as indicated in our response to reviewer 3 point 1, the heme-free fraction of the recombinant Sfh5 is also inactive by any measure we have at our disposal. We also now add the experiment that shows heme-free WT Sfh5 produced in yeast devoid of heme is NOT resuscitated for PITP activity -- unlike the heme-binding mutants (see response to reviewer 2, point 3). Our interpretation is that the mutations that abrogate heme binding have the added effect of permitting PtdIns-binding whereas the wild-type Tyr/His coordination motif is intrinsically nonpermissive for PtdIns-binding. Those new data are consistent with our initial interpretations.

> 3\) There is no functional evidence presented to prove that Sfh5, which is expressed at low levels and shows no deletion functional phenotype, or its unique heme-binding properties are important in yeast or any other organism. Is it possible Sfh5 could be vestigial in yeast? Do related proteins from other organisms (i.e., those that evolutionarily precede yeast) express Sfh5 with higher expression and more robust heme-dependent functional activities. If Figure 8---figure supplement 2 provides the only insight into the potential functional relevance of Sfh5, the authors should consider moving it to a main figure.

Whether this is a vestigial gene or not is a teleological question we cannot confidently answer. We agree that assessing the functions of Sfh5 orthologs in other systems is a likely next step. But we hope all agree this is well beyond the scope of this work. However, the fact that it is conserved across significant evolutionary distances suggests to us this is not vestigial.

> 4\) Crystallography: The authors show that Sfh5 is a homodimer using AUC; however, no dimerization was observed in the crystal structure. An issue related to this that should be addressed: when the sfh5_map_coeffs.mtz file provided by the authors is analyzed in CCP4, the Matthews_coef analysis (estimate of the number of asymmetric units in the unit cell) indicates there should be 4 molecules (e.g., two dimers?) in one unit cell with a solvent content \~52.2%. However, the authors solved the structure with 3 molecules in one unit cell. Other issues that should be addressed pertaining to the structure refinement include (1) the Ramachandran outliers in the validation report is 0.5%, which is inconsistent with 0% reported by the authors in the Table 1; (2) the percent of residues with favored Ramachandran is 86%, which can likely be improved; and (3) the R-factor gap (R~work~/R~free~) is large. Finally, the number of atoms in the protein (129) and ligand (5) reported by the authors in Table 1 needs to be corrected.

The AUC experiments were performed at physiological pH whereas the crystallization conditions were at pH 4.2 so the two results cannot be confidently compared. Regarding the Matthews_coef analysis, the calculated asymmetric unit content with 3 molecules gives a solvent content of 66.4% and with 4 molecules you get a solvent content of 55.1 %. Both are in the acceptable range for proteins. The SAD electron density showed only 3 polypeptide chains per ASU with no additional chain density or gaps in the packing identified.

1\) Regarding the inconsistency of the validation report vs. Table 1, we thank reviewer 4 for the careful examination. We mistakenly rounded to the whole and it is corrected now.

2\) Regarding improvement of the favored Ramachandran, as described above, only the density for chain B was well-ordered. The resultant model for chain B has 100% fit to electron density based on RSRZ values, and no Ramachandran outliers. Chain B model was used for all analysis and interpretation, as well as a guide to build chains A and C, which have large regions of poor density. We now explicitly state this in the text. These regions are the main contributors to the Ramachandran outliers. Imposing stricter geometry restrains by changing weights in the refinement leads to greater gap between R~free~ and R~work~.

3\) Regarding the R-factor gap, as stated above, this was a challenging structure to solve and build as chains A and C show large regions of disordered density in the original SAD maps and with model phases. Multiple attempts were made to rebuild the model and multiple data sets were sampled -- all sharing the same problems. We chose the best R~work~ and R~free~ combination that we could obtain and stopped the refinement once R~free~ started to increase when we attempted to fix geometry further (as suggested above).

4\) The values have been corrected in the Table 1. Thank you for pointing out this error.

> 5\) Figure 7: The authors prepared apo-myoglobin by methy-ethyl ketone extraction of heme from equine skeletal myoglobin for use in heme-transfer assays to determine if Sfh5 can exchange heme via detection of heme transfer to apo-myoglobin. However, they do not show a critical positive control showing that free heme can bind to their prepared apo-myoglobin to demonstrate the protein is functionally capable of binding heme.

That control is now included in a new Figure 8.

[^1]: These authors contributed equally to this work.
